



Papillomaviruses: a systematic review

Rodrigo Pinheiro Araldi^{1,2}, Suely Muro Reis Assaf¹, Rodrigo Franco de Carvalho¹, Márcio Augusto Caldas Rocha de Carvalho^{1,3}, Jacqueline Mazzuchelli de Souza^{1,2}, Roberta Fiusa Magnelli^{1,2}, Diego Grandó Módolo¹, Franco Peppino Roperto⁴, Rita de Cassia Stocco¹ and Willy Beçak¹

¹Laboratório de Genética, Instituto Butantan, São Paulo, SP, Brazil.

²Programa de Pós-graduação Interunidades em Biotecnologia, Instituto de Ciências Biomédicas (ICB), Universidade de São Paulo (USP), São Paulo, SP, Brazil.

³Programa de Aprimoramento Profissional (PAP), Instituto Butantan, São Paulo, SP, Brazil

⁴Dipartimento di Medicina Veterinaria e Produzioni Animali, Università degli Studi di Napoli Federico II, Napoli, Campania, Italy.

Abstract

In the last decades, a group of viruses has received great attention due to its relationship with cancer development and its wide distribution throughout the vertebrates: the papillomaviruses. In this article, we aim to review some of the most relevant reports concerning the use of bovines as an experimental model for studies related to papillomaviruses. Moreover, the obtained data contributes to the development of strategies against the clinical consequences of bovine papillomaviruses (BPV) that have led to drastic hazards to the herds. To overcome the problem, the vaccines that we have been developing involve recombinant DNA technology, aiming at prophylactic and therapeutic procedures. It is important to point out that these strategies can be used as models for innovative procedures against HPV, as this virus is the main causal agent of cervical cancer, the second most fatal cancer in women.

Keywords: bovine papillomavirus (BPV), bovine papillomatosis, carcinogenesis, natural history.

Received: May 09, 2016; Accepted: September 28, 2016.

A brief history of the papillomavirus (PVs) on carcinogenesis

In the last decades, novel diagnostic methods and therapies have been implemented in an attempt to combat cancer. However, the number of patients that succumb to the disease has increased globally (Varga *et al.*, 2014). This negative result emphasizes the complexity of the oncogenic process, which has a multifactorial cause. Among the etiological factors associated to cancer are the infectious agents, such as bacteria and viruses.

The association between cancer and infectious agents has been discussed for centuries (Graner, 2000). In 1858, George B. Wood stated in his book *Practice of Medicine* that cancer could be disseminated as an infectious disease (Graner, 2000). However, the association between cancer and infectious agents was only implied in the second half of 19th century by Rudolf Maier (Graner, 2000; zur Hausen, 2009). The major difficulty in demonstrating this association can be attributed to the time-lapse of 15-40 years be-

tween the infection and the development of the first clinical signs that would allow cancer diagnosis (zur Hausen, 2009). Yet, in the last decades, the involvement of infectious agents with cancer has aroused great attention, as one in ten human malignancies is caused by these pathogens (Ribeiro-Müller and Müller, 2014).

Current studies estimate that 23% of all human malignancies are associated with infectious agents (zur Hausen, 2009; WHO 2013; Brücher and Jamall, 2014; Bravo and Felez-Sanchez, 2015). Among them, human papillomavirus (HPV) is responsible for 27.9% (zur Hausen, 2009) to 30.0% (Bravo *et al.*, 2010) of all incident cancer cases in the world. This data is very concerning, once 75% of the global population lives in developing countries (Marrazzo and Holmes, 2013), where the lack of information about the HPV and others sexually transmitted diseases (STD) contributes to the increase of HPV-associated cancers. According to the World Health Organization (WHO) (<http://www.who.int/mediacentre/factsheets/fs380/en/>), 85% of cervical cancer cases occurs in less developed countries.

Papillomaviruses (PVs) are not only associated to human cancers, but also with animal malignancies. Although

Send correspondence to Willy Beçak. Laboratório de Genética, Instituto Butantan, Avenida Vital Brasil 1500, 00553900 São Paulo, SP, Brazil. E-mail: wbecak@yahoo.com.br

there is no epidemiological data about the number of PV-associated incident animal cancers, this association is recognized since 1932 (Shope and Hurst, 1933; Graner, 2000). Moreover, veterinary research demonstrates an increase in both benign and malignant tumors (Misdorp, 1996), particularly in domestic animals (cats and dogs). Furthermore, animal neoplasms are important models for the study of human oncogenic process (Misdorp, 1996), by allowing the identification of molecular mechanisms associated to carcinogenesis (Cotchin, 1962, 1976) and novel therapeutics (Misdorp, 1996), and emphasizing the importance of comparative oncology.

In this review, we summarize relevant data and advances in papillomaviruses biology, including viral evolution, pathogenic mechanism of viral proteins and oncoproteins, ways of transmission, pathogenesis and oncogenesis. We also discuss the importance of BPV as a study model for HPV-associated oncogenic process.

Genome organization of PVs

PVs are small, circular, double-stranded DNA viruses, able to infect all vertebrates (zur Hausen, 2009), as shown in Table 1. PVs belong to *Papillomaviridae* family (Bravo and Felez-Sanchez, 2015), which presents tropism

for epithelial and mucous tissue (Cotchin, 1962). These viruses have genomes between 6,953 bp (CmPV1 - *Chelonia mydas* papillomavirus type 1) to 8,607 bp (CRPV1 - *Cotton rabbit* papillomavirus type 1), divided in three regions: early (E), late (L) and long codon region (LCR), as showed in Figure 1 (van Doorslaer, 2013). The E region codifies replication proteins (E1, E2, E4), and the oncoproteins E5, E6 and E7 (Bocaneti *et al.*, 2014). The L region codifies capsid proteins (L1 and L2) (van Doorslaer, 2013). The LCR does not codify any protein, but has the origin of replication (*ori*) (van Doorslaer, 2013). Currently, more than 280 different types of PVs are described. More than 200 types infect humans (Munday, 2014), which are classified in 49 genera according to the International Committee on Taxonomy of Viruses (ICTV) (Araldi *et al.*, 2015b). Phylogenetic classification of PVs are based on the L1 open reading frame (ORF) sequence homology, since this is the most conserved ORF among the different PV types (de Villiers *et al.*, 2004, de Villiers, 2013; Melo *et al.*, 2014; Munday *et al.*, 2015). According to this system, differences over 10% on L1 ORF sequence determine a novel virus type, while differences between 2-10%, a novel virus subtype (de Villiers, 2013).

Table 1 - Papillomaviruses identified in different vertebrates

Species	Virus	References
Bovines	<i>Bos taurus</i> papillomavirus or Bovine papillomavirus (BPV)	Araldi <i>et al.</i> (2015b) Araldi <i>et al.</i> (2014a) Carvalho <i>et al.</i> (2013) Stocco dos Santos <i>et al.</i> (1998)
Canines	Canine oral papillomavirus (COPV) or <i>Cannis familiaris</i> papillomavirus (CfPV)	Nicholls <i>et al.</i> (2001) Zaugg <i>et al.</i> (2005)
Deer	<i>Capreolus capreolus</i> papillomavirus (CcPV) or <i>Cervus elaphus</i> papillomavirus (CePV)	Král <i>et al.</i> (2015)
Felines	<i>Felis catus</i> papillomavirus (FcaPV)	Munday (2014)
Rabbit	Cotton rabbit papillomavirus (CRPV)	Shope and Hurst (1933) Danos <i>et al.</i> (1985) Rashad and Evans (1967)
Raccoon	<i>Procyon lotor</i> papillomavirus (PIPV)	Ng <i>et al.</i> (2015)
Seaotter	<i>Enhydra lutris</i> papillomavirus (EIPV)	Ng <i>et al.</i> (2015)
Sheep	<i>Ovis aries</i> papillomavirus (OaPV)	Alberti <i>et al.</i> (2010)
Mice	<i>Mus musculus</i> papillomavirus (MmPV)	Handisurya <i>et al.</i> (2013)
Birds	<i>Fulmarus glacialis</i> papillomavirus (FgPV) <i>Francolinus leucoscepus</i> papillomavirus (FIPV) <i>Fringillacoelbs</i> papillomavirus (FcPV) <i>Psittacus erithacus</i> papillomavirus (PePV)	Gaynor <i>et al.</i> (2015a) Moreno-Lopez <i>et al.</i> (1984) Van Bresseem <i>et al.</i> (2007)
Rat	<i>Rattus norvegicus</i> papillomavirus (RnPV)	Hansen <i>et al.</i> (2015)
Monkey	<i>Rhesus macaca</i> papillomavirus (RmPV)	Roberts (2015)
Human	Human papillomavirus (HPV)	zur Hausen (2009) Herbster <i>et al.</i> (2012)




Figure 1 - BPV genome organization and differential protein expression: double strand DNA circular genome divided in early (E), late (L) and long codon region (LCR). Early region codifies replication proteins (E1, E2, E4, E5, E6 and E7). These proteins are expressed from basal to cornified layer, being involved with virus replication and virion release (E4). Late region codifies L1 and L2 capsid proteins. Once these structural proteins are involved with virus assembly, they are expressed in the most differentiated epithelium layers (granular and cornified).

Evolutionary history of papillomaviruses

Although the virus origin is still uncertain (Bernard, 1994; Holland and Domingo, 1998), studies about PVs suggest that they arose concomitantly with tetrapods in the Carboniferous period of the Paleozoic era (330 million years ago) (Rector and Van Ranst, 2013). This makes the PVs one of the oldest and largest known virus family (Cubie, 2013; Rector and Van Ranst, 2013).

Studies based on molecular phylogeny suggest that these viruses originated in Africa, from where they disseminated to all continents (Bernard, 1994). It was not a pandemic dissemination, occurring over one million years (Bernard, 1994).

PVs genomic diversification occurred together with mammals diversification, being influenced by multiple evolutionary forces (Bravo *et al.*, 2010), such as the addition of sequence boxes, previously present in their host (García-Vallvé *et al.*, 2005). Thus, PVs co-evolved with their respective host (Gottschling *et al.*, 2007). An evidence of this co-evolution is the similarity in guanine and cytosine (G + C) content; HPVs have 41-49% of G + C, and humans

40-42% (Black, 1968). Another evidence of this co-evolution is seen with the use of *in situ* hybridization probe for Shope papilloma virus (CRPV), which presents homology with the rabbit genome sequences (Black, 1968). Moreover, replicative mechanisms of PVs and their host are similar, reinforcing co-evolution (Leatherwood, 1998). These data suggest that PVs could have originated from genomic fragments of amniotes' common ancestor (van Doorslaer and Burk, 2010; Rector and Van Ranst, 2013; van Doorslaer, 2013).

Animal domestication favored the enzootic transmission of PVs (Gottschling *et al.*, 2007). In this process, novel strategies of adaptation were required to guarantee the infection of novel hosts (Gottschling *et al.*, 2011). These adaptations favored PVs evolution, conferring specificity in terms of host to all members of *Papillomaviridae* family, except for BPV, which is able to promote cross-infection (Bernard, 1994).

Based on this, García-Vallvé *et al.* (2005) described a hypothetical model to recreate PVs evolution. This model supports the existence of a proto-papillomavirus, com-

prised by URR-E1-E2-L2-L1 genomic regions, able to infect primitive amniotes. Along mammals divergence (150 million years ago), this proto-papillomavirus was added with E6 and E7 ORFs. From this moment, PVs' interaction with their host became more specific, resulting in a co-evolution. This process also resulted in the addition of E5 ORF in the hot spot between E2 and L2 ORFs (Bravo and Felez-Sanchez, 2015). Phylogenetic analyses point out that PVs only acquired oncogenic potential after they infected humans (García-Vallvé *et al.*, 2005). This suggests that BPV could have originated from HPV transmission to bovines, as a consequence of animal domestication (García-Vallvé *et al.*, 2005), which would justify the similarities between these viruses, making the BPV a useful model to HPV studies (Campo, 2006; Borzacchiello and Roperto, 2008; Munday, 2014).

Non-oncogenic early (E) proteins expressed by PVs: E1, E2 and E4

E1 and E2 ORFs are expressed after PV infection, once their genetic products are essential to virus replication (Ferraro *et al.*, 2011). The E1 ORF is the second most conserved sequence among the PVs (Forsslund *et al.*, 1999; Enemark *et al.*, 2000), and codifies the E1 protein, which has three functional domains: (1) N-terminal, that induces Cdk2 phosphorylation, (2) C-terminal, that acts as ATP-dependent helicase and (3) central, that binds to E2 protein, resulting in E1-E2 complex (García-Vallvé *et al.*, 2005; Wallace and Galloway, 2014). The E1-E2 complex binds to viral replication origin (*ori*) present in LCR (Enemark *et al.*, 2000; Schuck and Stenlund, 2015). Next, the E1 protein forms the di-hexameric complex in *ori* (Gauson *et al.*, 2016), and recruits replication proteins such as topoisomerase I, DNA polymerase α and replication protein A (RPA), that need to replicate (Schuck and Stenlund, 2015). Due to its helicase activity, the E1 protein can induce simple strand breaks (SSBs) and double strand breaks (DSBs) in host DNA (Schuck and Stenlund, 2015).

E2 is a modular protein, composed by two domains: (1) C-terminal and (2) transactivation N-terminal (Wallace and Galloway, 2014). The E2 C-terminal binds to Brd4 protein (Gauson *et al.*, 2016). The E2-Brd4 complex interacts with lysine residues in acetylated histones (Schweiger *et al.*, 2006, 2007), resulting in an equitable distribution of virus copies after cytokinesis (Campo, 2006; Wallace and Galloway, 2014).

The E2 protein also acts as an E6 and E7 transcriptional regulator (García-Vallvé *et al.*, 2005; Bogaert *et al.*, 2008; Cai *et al.*, 2013). In high levels, E2 binds to 5'-ACCG(N)₄CGGT-3' palindromic sequence present in four E2 binding sites (E2BSs) in E6 and E7 promoter (P97) (Cai *et al.*, 2013). This inhibits RNA polymerase II binding, repressing E6 and E7 transcription (García-Vallvé *et al.*, 2005). However, under low expression levels, E2 recruits

transcription factors necessary to form the open transcription complex (Helfer *et al.*, 2014; Jang *et al.*, 2014). In addition, E2 is an important epigenetic regulator, since the protein interacts with the p300/CBP-p/CAF global transcription activator (Wallace and Galloway, 2014). This interaction leads to *TP53* hypo-acetylation, reducing p53 expression levels (Wallace and Galloway, 2014).

The E4 ORF codifies a family of proteins produced by splicing followed by post-translational modifications (Campo, 1997a). The E4 protein is the most expressed protein of PVs (Doorbar, 2013). For this reason, E4 is easily detected in suprabasal and granulosum layers of epidermis (Rampias *et al.*, 2013), being recognized as important hallmark of PVs pathogenic activity (Doorbar, 2013). The E4 protein interacts with cytokeratin filamentous, contributing to viral replication (Campo, 1997a). Moreover, E4 is associated to virus maturation and extracellular matrix (MEC) remodeling (Ferraro *et al.*, 2011).

Late proteins: L1 and L2

The L1 ORF is the most conserved among PVs (Bernard *et al.*, 2006; Haga *et al.*, 2013), and for this reason it is employed in virus classification (Haga *et al.*, 2013; de Villiers, 2013). The L1 protein has 55 kDa (Buck *et al.*, 2013), and is able to self-organize in pentameric structures that compose the viral capsid (Ribeiro-Müller and Müller, 2014). It has a central role in viral infection mechanism, allowing the capsid anchorage to heparin sulfate receptors present in cell membrane (Florin *et al.*, 2012). Considering that L1 is a late protein, it is expressed in the most differentiated epithelium layers (Buck *et al.*, 2004). Therefore, L1 immunodetection has been considered the main evidence of productive infection (Nasir and Reid, 1999; Costa and Medeiros, 2014; Melo *et al.*, 2015; Araldi *et al.*, 2015b), which is characterized by the virus assembly (Green, 1972).

The L2 protein has 64-78 kDa (Wang and Roden, 2013). The molecular weight variation is a consequence of post-translational modifications (Wang and Roden, 2013). During the assembly of PV particles, L2 binds to viral DNA, contributing to encapsidation and then to viral release (García-Vallvé *et al.*, 2005; Campo, 2006).

A third structural protein (L3) has been described as present exclusively in BPV-4 (Catroxo *et al.*, 2013). However, its function remains unclear.

Oncogenic proteins expressed by PVs: E5, E6 and E7

E5 oncoprotein

The E5 is the most studied BPV oncoprotein and its transforming potential is known since 1960 (Roberts, 2015). The E5 oncoprotein can induce both *in vivo* and *in*

in vitro transformation (Campo, 2006; Silvestre *et al.*, 2009; Rampias *et al.*, 2013; DiMaio, 2014). Furthermore, it is responsible for the fibrotropism verified in fibropapillomas and equine sarcoids (Chambers *et al.*, 2003a; DiMaio, 2014).

PV-1 E5 is a transmembrane protein (Costa and Medeiros, 2014), with 43–44 amino acids, characterized by the presence of a central hydrophobic region, which acts as a transmembrane domain (Burkhardt *et al.*, 1989; Tomita *et al.*, 2007; DiMaio, 2014). E5 also presents two cysteine residues in the C-terminal region that confers stability for the homodimer composed by two E5 monomers (DiMaio, 2014).

The E5 oncoprotein induces cell membrane composition and dynamic changes, affecting the Golgi complex (Burkhardt *et al.*, 1989; García-Vallvé *et al.*, 2005; Balcos *et al.*, 2008). This occurs because E5 is able to bind to the H⁺-ATPase vacuolar subunit (Burnett *et al.*, 1992), promoting Golgi inner membrane alkalization (Krawczyk *et al.*, 2010). This leads to major histocompatibility complex II (MHC-II) heavy chain sequestration, conferring an evolutionary mechanism of immune evasion (Venuti *et al.*, 2011). In addition, the E5 oncoprotein inhibits the expression of MHC-I and cyclooxygenase (COX) (Borzacchiello, 2007; Tomita *et al.*, 2007; Venuti *et al.*, 2011). These mechanisms contribute to viral infection persistence.

The E5 oncoprotein can bind to ductin, a connexon component, inhibiting the gap junction formation and therefore cell communication (Campo, 1997a; Borzacchiello and Roperto, 2008). E5 also contributes to focal adhesion loss, affecting cell differentiation (Rampias *et al.*, 2013).

The E5 oncoprotein is able to bind to platelet-derived growth factor receptor beta (PDGFβR) (Chambers *et al.*, 2003a; DiMaio, 2014; Costa and Medeiros, 2014). PDGFβR is a tyrosine-kinase receptor present in the cell surface (Nicolas *et al.*, 2013). Under normal conditions, PDGFβR is activated by PDGF, which promotes receptor dimerization (DiMaio, 2014) and activation of different kinases, such as: A-cdk2, MAPK, JNK, PI3K and C-Src (Chambers *et al.*, 2003a; Borzacchiello, 2007). However, E5 binding to PDGFβR can lead to phosphatidylinositol-3-kinase (PI3K)-mediated Akt pathway activation (Costa and Medeiros, 2014). This activates the D3 cyclin, promoting cell cycle deregulation (Venuti *et al.*, 2011; Costa and Medeiros, 2014). The PI3K/Akt pathway activation also induces metabolic deregulation in the host cell (Vivanco and Sawyers, 2002; Hennessy *et al.*, 2005). PDGFβR activation also recruits pericytes, stimulating angiogenesis (Pietras and Ostman, 2010).

E6 oncoprotein

E6 is a small oncoprotein with 151–158 (HPV) (Ristriani *et al.*, 2000; Boulet *et al.*, 2007) or 137 amino acids (BPV-1) (Tong *et al.*, 1998; Mazzuchelli-de-Souza *et al.*,

2013), without enzymatic activity (Tan *et al.*, 2012a). The E6 oncoprotein is characterized by the presence of a class I PDZ domain (PSD-95/Dlg/ZO-1), which is located in the C-terminal, and four PVs conserved motifs (Cys-X-X-Cys) (Chen *et al.*, 1997; Tong *et al.*, 1998; Nominé *et al.*, 2006; Boon *et al.*, 2015). The PDZ domain is found in BPV (Mischo *et al.*, 2013) and high-risk HPVs (Boon *et al.*, 2015) and can interact with different proteins, promoting loss of intercellular contact and cell polarity (Boon *et al.*, 2015).

The HPV E6 oncoprotein can form a trimeric complex with E6AP ubiquitin ligase and p53 (Zanier *et al.*, 2005, 2007; Tan *et al.*, 2012a). This complex is responsible for the proteolytic degradation of p53 (Zanier *et al.*, 2005; Liu and Baleja, 2008), which directs the p53 to 26S proteasome (Cai *et al.*, 2013). The HPV-5 and 8 as well as BPV E6 oncoprotein interact with the CBP/p300 complex (Werness *et al.*, 1990; Zimmermann *et al.*, 2000; Liu *et al.*, 2005), promoting p53 downregulation (Zimmermann *et al.*, 1999). The loss of p53 contributes to genomic instability verified in cells infected by PVs (Araldi *et al.*, 2013, 2015b), as well as in cells treated with BPV-1 E6 recombinant oncoprotein (Araldi *et al.*, 2015a).

The overexpression of p53 represents a threat to viral replication (Shamanna *et al.*, 2013). For this reason, different oncogenic viruses express proteins able to promote p53 deregulation. Among these proteins are antigen T of SV40, adenovirus E1B, hepatitis B virus (HBV) HBx and PVs E6 (Shamanna *et al.*, 2013; Cuninghame *et al.*, 2014). Thus, p53 deregulation is a characteristic shared by oncogenic viruses.

The E6 protein can interact with paxillin (Turner, 2000; Zanier *et al.*, 2005) and AP-1 gamma subunit clathrin adapter (Tong *et al.*, 1998). These interactions can lead to cytoskeleton alterations, affecting the vesicular traffic. E6 can also interact with fibulin 1, contributing to invasiveness phenotype (Moody and Laimins, 2010).

Studies have also demonstrated that E6 oncoprotein can induce cell transformation (Liu *et al.*, 2002) and immortalization (Boon *et al.*, 2015) due to the up-regulation of telomerases (Cuninghame *et al.*, 2014). This occurs because E6 promotes *FOXM1* overexpression, resulting in cyclin B1, D1 and *cdc25* expression and, therefore, cell proliferation (Chen and Lee, 2015). In addition, E6 is able to bind to LXXL motif of *MAML1* transcriptional regulator, inhibiting the *Notch* signaling (Tan *et al.*, 2012a; White and Howley, 2013). The E6 oncoprotein of both HPV and BPV also promotes energy metabolic deregulation, contributing to cell transformation (Araldi *et al.*, 2016).

E6 inhibits the SSB repair system, leading to genomic instability. This occurs because the oncoprotein interacts with XRCC1 and O⁶-methylguanosine-DNA-methyltransferase protein, which is recruited during the SSB repair (Wallace and Galloway, 2014). E6 also leads to cyto-

genetic damages (Wallace and Galloway, 2014) and stimulates neosis (Araldi *et al.*, 2015a).

E7 oncoprotein

The E7 oncoprotein has 127 amino acids (Borzacchiello, 2007), and is able to bind to LXCXE conserved motif of pRb tumor suppressor protein (Moody and Laimins, 2010; White and Howley, 2013). This binding results in pRb phosphorylation, leading to E2F factor translocation to the nucleus (Longo, 2013). The E2F factor recruits different chromatin modifiers, including histone deacetylases (HDAC) (Moody and Laimins, 2010). Thus, the E7 oncoprotein induces the constitutive expression of E2F-responsive genes, such as cyclin A and E (Moody and Laimins, 2010), leading to S and G2/M cell cycle phase increase (Sacco *et al.*, 2003; Ferraro *et al.*, 2011). The interaction between viral oncoproteins and pRb is not exclusive of PVs, being also observed with adenovirus E1A and antigen T of SV40 (White *et al.*, 2015).

Studies have demonstrated that E7 induces DNA breaks, contributing to cell cycle deregulation (Park *et al.*, 2014; Araldi 2015; Araldi *et al.*, 2015b). In addition, the E7 oncoprotein increases the *Sirt1* deacetylase expression levels, modulating γ -H2AX activity (Park *et al.*, 2014), a protein that participates in DSB repair (Sedelnikova and Pilch, 2003; Chowdhury *et al.*, 2005). Thus, the E7 oncoprotein inhibits DSB repair, resulting in genomic instability.

Bovine papillomavirus (BPV): first reports and questions

In 1986 in an intriguing paper by Campo and Jarret (1986) reported the description of six different BPV types (BPV-1 to BPV-6) classified into two subgroups: subgroup A, that promotes fibropapillomas, and subgroup B, which leads to true epithelial papillomas. The report also showed that the BPV-4, a member of subgroup B, was the etiological agent of papillomas of the upper digestive tract, which could become carcinomas in animals feeding on a specific bracken fern pasture (*Pteridium aquilinum*). Later, Walter-Moura *et al.* (1988) verified the increase of chromosome aberrations in cells obtained from short term peripheral lymphocytes collected from bovines afflicted with bovine enzootic hematuria (BHE) that were exposed

to pastures with bracken fern. These studies were reinforced by following reports, demonstrating that carcinogenesis is associated to the interaction between BPV and carcinogens present in the fern, such as quercetin and ptaquilosides (Pennie and Campo, 1992; Shahin *et al.*, 1999; Potter and Baird, 2000; Beniston *et al.*, 2001; Leal *et al.*, 2003; Lioi *et al.*, 2004). These studies brought new questions to be answered: how can the co-factor act in synergism with the virus? Why can these effects be detected in peripheral blood, considering that the virus is epithelial? Or, could the effect on chromosomes be only related to bracken fern compounds?

BPV and bovine papillomatosis (BP)

BPV is a cosmopolitan virus, worldwide distributed, independently of the level of expertise on livestock exploration (He *et al.*, 2014). It is estimated that 60% of Brazilian cattle herd is infected by BPV (Stocco dos Santos, *et al.*, 1998). However, that rate can be higher, once virus infection can be asymptomatic (Araldi *et al.*, 2013; Silva *et al.*, 2013a). Furthermore, the absence of epidemiological studies about BPV distribution could underestimate the real percentage of infected animals, representing a notorious difficulty in attempting to develop vaccines, once we do not know the prevalent virus types in each country.

BPV infection is endemic in both dairy and beef cattle breeding (Claus *et al.*, 2009; Araldi, 2015.; Araldi *et al.*, 2015b). However, BPV presents a predilection for dairy cattle (Araldi, 2015). The virus is the causal agent of bovine papillomatosis (BP) (Muro *et al.*, 2008), an infectious, contagious and neoplastic disease, characterized by the presence of multiple benign tumors (papillomas) (Figure 2) that can regress spontaneously or progress to malignant neoplasms (Campo, 2002; Turk *et al.*, 2005; Yagui *et al.*, 2006; Borzacchiello and Roperto, 2008; Araldi *et al.*, 2014b; Bocaneti *et al.*, 2014). Although BP affects preferably young cattle, the disease can occur at all ages (Börkű *et al.*, 2007). The persistence of papillomas can lead to feeding and breathing difficulties, requiring the animal's euthanasia (Campo, 2002). Moreover, BP decreases growth rate and induces weight loss (Munday, 2014). The disease also predisposes bovines to opportunist bacterial infections (Munday, 2014), mainly in breast and mammary glands,



Figure 2 - Adult bovine (Simmental breed) with bovine papillomatosis (BP): skin papillomas on face (A), dewlap (B) and back (C).

which can result in mastitis, causing pain, reducing milk production (Campo, 2002; Muro *et al.*, 2008; Lindsey *et al.*, 2009; Santos *et al.*, 2014) and causing depreciation of leather value (Monteiro *et al.*, 2008).

Cutaneous papillomas are proliferative benign tumors, with complex pathogenesis (Börkú *et al.*, 2007). These neoplasms commonly arise in vascularized areas exposed to physical attrition (Özsoy *et al.*, 2011). Histologically, papillomas are characterized by epithelium hyperplasia, showing an enlargement of interpapillary ridge that extend above dermis (Monteiro *et al.*, 2008). Morphologically, they are classified in: (1) typical - exophytic masses, with “cauliflower” aspect, presenting a wide or narrow insertion base, (2) pedunculated - exophytic masses connected by a narrow base with a peduncle shape, (3) atypical or flat - dense and flat exophytic masses entirely connected with the tissue, (4) filamentous - exophytic masses with highly keratinized surface and a thin base, present in mammary glands and (5) rice-form - small papillomas with rice-like shape (Monteiro *et al.*, 2008).

Currently, 15 types of BPV are described (Munday *et al.*, 2015), and classified in four genera: *Deltapapillomavirus* (BPV-1, 2, 13 and 14), *Epsilonpapillomavirus* (BPV-5 and 8), *Xipapillomavirus* (BPV-3, 4, 6, 9, 10, 11, 12 and 15) and *Dyoxipapillomavirus* (BPV-7) (Melo *et al.*, 2014; Grindatto *et al.*, 2015; Munday *et al.*, 2015; Silva *et al.*, 2016). *Delta* and *Epsilonpapillomavirus* are associated with both papillomas and fibropapillomas, while *Xipapillomavirus*, only to squamous papillomas (Tomita *et al.*, 2007; Yuan *et al.*, 2007; Tan *et al.*, 2012b; Araldi, 2015; Araldi *et al.*, 2015b).

Although there is no epidemiological study that allows the definition of BPV distribution, BPV-1 and 2 seem to be the most frequently identified virus types (Pathania *et al.*, 2012; Melo *et al.*, 2014; Santos *et al.*, 2014; Alcântara *et al.*, 2015; Araldi, 2015; Cota *et al.*, 2015; Araldi *et al.*, 2015b). Moreover, these viruses are associated with both benign and malignant neoplasms (Gopalkrishna *et al.*, 1995; Nasir and Campo, 2008; Cota *et al.*, 2015). However, the global distribution of BPV is not homogenous (Santos *et al.*, 2014). BPV-1 and 2 have closely related serotypes (Shafti-Keramat *et al.*, 2009), associated with urinary bladder malignant neoplasms (Wosiacki *et al.*, 2005; Balcos *et al.*, 2008; Roperto *et al.*, 2008; Maiolino *et al.*, 2013; Cota *et al.*, 2015). BPV-4 infection is an important cause of upper digestive tract cancer development (Tsirimonaki *et al.*, 2003; Nasir and Campo, 2008; Lucena *et al.*, 2011). Studies also show that BPV-13 is associated to urothelial carcinomas (Roperto *et al.*, 2015).

Diagnostic methods

Studies about BPV diversity and prevalence are mandatory to develop novel therapeutic methods (Silva *et al.*,

2013b), since immunity is species-specific (Claus *et al.*, 2007). Therefore, diagnosis is crucial.

Different methods have been implemented to identify PVs, such as: *Southern blot* (Leto *et al.*, 2011), immunohistochemistry (IHC) (Elzein *et al.*, 1991; Araldi *et al.*, 2015b), chromogenic *in situ* hybridization (CISH) (Melo *et al.*, 2015), electron microscopy (Araldi *et al.*, 2014b) and PCR using specific and/or degenerate primers (Stocco dos Santos *et al.*, 1998; Araldi *et al.*, 2013, 2014a, 2015b; Melo *et al.*, 2014). Among these techniques, PCR is the most used due to its high sensitivity (Leto *et al.*, 2011). Moreover, using the restriction fragment length polymorphism of PCR products (PCR-RFLP) allows to identify BPV type (Carvalho *et al.*, 2013), since this method shows a correlation of 95% with the results obtained using DNA sequencing (Martens *et al.*, 2001a; Carvalho *et al.*, 2013; Kawauchi *et al.*, 2015).

Although real-time PCR (qRT-PCR) allows to determine the number of viral copies, this method has the lowest reproducibility (Guo *et al.*, 2012). For this reason, PCR followed by DNA sequencing represents the most common method to identify and typify BPVs (Melo *et al.*, 2014; Araldi *et al.*, 2014b). However, there is no “gold-standard” primer employed in PVs identification (Antonsson *et al.*, 2010).

On the one hand, although the specific primers have higher sensitivity than degenerate primers, they cannot identify the 14 BPV types simultaneously (Araldi *et al.*, 2014b). In addition, specific primers do not allow to identify novel virus types and subtypes (Araldi *et al.*, 2014b). Moreover, evidence indicates that a specific primer for BPV-1 can anneal to BPV-2 (Haga *et al.*, 2013), once these virus types are considered serotypes-like (Shafti-Keramat *et al.*, 2009). However, in a comparative study using complete genomes of BPV-1-6 in 2014 we demonstrated the BPV-1 primer specificity (Araldi *et al.*, 2014b).

Among the degenerate primers described in the literature, FAP59/64 (Forslund *et al.*, 1999) is the most employed in both BPV and HPV identification. This primer was designed based on the L1 ORF homology of HPV (Forslund *et al.*, 1999) and later optimized to identify BPV DNA sequences (Ogawa *et al.*, 2004). Furthermore, the use of FAP59/64 primer already allowed to identify novel BPV types, including BPV-9 and 10 (Hatama *et al.*, 2008). However, despite of these advantages of degenerate primers, there are several reports showing their low sensitivity. For instance, MY09/11, another degenerate primer frequently used in HPV diagnosis, was unable to identify BPV and HPV sequences in clinical samples (Martelli-Marzagão *et al.*, 2010; Zhu *et al.*, 2014) or copies of complete cloned genome (Araldi *et al.*, 2014b).

Although PCR is commonly used to identify PV DNA sequences, the method does not allow to identify their localization and physical state (episomal or integrated). Therefore, CISH represents an additional method used to

demonstrate the physical state of these viruses (Black, 1968; Munday, 2014; Melo *et al.*, 2015). Another additional technique to identify PVs is L1 immunodetection (Nasir and Reid, 1999; Longworth and Laimins, 2004; Roperto *et al.*, 2011; Munday, 2014; Melo *et al.*, 2015; Araldi *et al.*, 2015b), which not only allows identification of the viral presence, but also provides an important evidence of productive infection (Nasir and Reid, 1999; Roperto *et al.*, 2011; Melo *et al.*, 2015).

Histopathological analysis of BPV-infected lesions is a differential diagnosis method, which allows to identify intra-epithelial neoplasms with oncogenic potential (Monteiro *et al.*, 2008; Araldi *et al.*, 2015b).

BPV infection pathway and histopathological alterations

BPV transmission can occur by direct (animal-animal) or indirect contact with contaminated surfaces (Muro *et al.*, 2008; Cubie, 2013). Studies also show that the virus can be transmitted by flies (Finlay *et al.*, 2009) and ticks (Muro *et al.*, 2008).

Studies of PV infection are based on the prototype BPV-1 (Florin *et al.*, 2012). According to the literature, the viral infection requires a tissue micro-injury, exposing heparin sulfate proteoglycan receptors (Ljubojevic and Skerlev, 2014; Greber, 2016), which are needed for BPV L1 anchorage (Hartl *et al.*, 2011; Buck *et al.*, 2013). This is confirmed by treatment with heparinase preventing viral infection (Kines *et al.*, 2016). The micro-injury is necessary for the virus to access basal keratinocytes (Liu and Baleja, 2008), where the virus cycle begins (Campo, 1997a). Current studies also show that integrin $\alpha 6$ (CD49f) and integrin 332 (laminin 5) are targets for L1 binding (Sibbet *et al.*, 2000; Florin *et al.*, 2012).

The L1 binding to heparin sulfate leads to conformational changes in capsid icosahedral structure (Buck *et al.*, 2013). This exposes the L2 N-terminal to be cleaved by furin protein, present in the cell membrane (Buck *et al.*, 2013). This cleavage induces a second capsid conformational change, allowing L2 to bind to different receptors, such as integrin $\alpha 2\beta 4$ (Buck *et al.*, 2013). Next, the virions are internalized by an clathrin-dependent endocytosis mechanism, resulting in cytoplasmic vesicles that associate to lysosomes (Day *et al.*, 2003). The lysosomal acid content release promotes pH alterations in capsid proteins, resulting in viral DNA release (Day *et al.*, 2003). The BPV genome is found in episomal form (Campo, 2002; Munday, 2014; Cota *et al.*, 2015), while HPV can integrate in fragile sites of the host genome (Monte and Peixoto, 2010; Moody and Laimins, 2010; Munday, 2014). A current study based on qRT-PCR, showed that cutaneous papillomas have about 2.210^4 viral copies (Cota *et al.*, 2015).

PVs do not codify polymerase (Moody and Laimins, 2010). For this reason, these viruses induce the S-phase en-

try, which was verified in BPV-infected cells (Potocki *et al.*, 2014), in a process known as amplification (Moody and Laimins, 2010). Due to the stimulation of cell proliferation, BPV induces mitotic stress (Potocki *et al.*, 2014), resulting in cytogenetic aberrations (Stocco dos Santos *et al.*, 1998; Melo *et al.*, 2011; Araldi *et al.*, 2013; Campos *et al.*, 2013). Moreover, the viral hyperproliferative action leads to the exophytic mass development as a consequence of acanthosis (Cubie, 2013; Munday, 2014; Araldi *et al.*, 2015b). As occurs with epithelium differentiation and virus assembly, a keratinization process is verified (Ferraro *et al.*, 2011). This process is histologically characterized by the increase of keratin granules in the granular layer (Ferraro *et al.*, 2011; Araldi *et al.*, 2015b).

Virus assembly is observed in the most differentiated epithelium layers (Munday, 2014), where the virion release occurs by cell degeneration (Brobst and Hinsman, 1966; Buck *et al.*, 2013). This process results in koilocyte formation. The term koilocyte comes from the Greek word *koillos*, which means "cavity" (Ferraro *et al.*, 2011). Koilocyte formation results from the cytopathic effect of E5 and E6 oncoproteins, although the molecular mechanism that results in cell vacuolization remains unclear (Krawczyk *et al.*, 2008). However, the cytoplasmic vacuolization contributes to cell fragility and virion release (Krawczyk *et al.*, 2008; Wang and Kieff, 2013). In this sense, koilocytes are cells destined to apoptosis, which emerges as a consequence of DNA replication and macromolecule synthesis inhibition.

After viral assembly, virions are released in the corneum layer, allowing infiltration in the keratin matrix (Brobst and Hinsman, 1966; Buck *et al.*, 2013). This mechanism confers an immune evasion, since the icosahedral morphology of PVs is immunoreactive (Buck *et al.*, 2013). In addition, keratin confers physical protection for virions, as they are non-enveloped.

BPV as a model for HPV

HPV is species-specific, infecting exclusively humans (Koller and Olson, 1972; Campo, 2002). This specificity was demonstrated in the 1970s, when calves, hamsters, ponies and Rhesus monkeys were inoculated with BPV and HPV virions isolated by ultracentrifugation (Koller and Olson, 1972). However, only BPV was able to infect the species (Koller and Olson, 1972). Due to its capability to infect different species and the pathogenic and morphological characteristics shared with HPV (Munday, 2014), BPV has been used as a prototype to study PV biology and oncology (Koller and Olson, 1972; Campo, 2002; Liu *et al.*, 2005; Campo, 2006; Costa and Medeiros, 2014). Therefore, research involving BPV has contributed with the understanding of viral oncogenesis (Costa and Medeiros, 2014; Munday, 2014). Based on these data, the next sections will focus on BPV and its host interaction.

Equine sarcoid: an example of cross-infection

Although considered epithelial- and mucous-tropic, some BPV types, especially *Deltapapillomavirus*, can infect fibroblasts causing sarcoma-like lesions, known as equine sarcoid (Chambers *et al.*, 2003b; Geissshüsler *et al.*, 2016). Equine sarcoid was first described by Jackson (1936), being considered a biphasic neoplasia, since it affects both epidermis and dermis. Equine sarcoid is the most frequent benign skin neoplasia observed in horses that are 1-6 years old (Jackson, 1936; Otten *et al.*, 1993; Nasir and Reid, 1999; Martens *et al.*, 2000; Bergvall, 2013; Mosseri *et al.*, 2014), affecting 11.5% of all horses (Knottenbelt, 2005). Differently from papillomas, sarcoids rarely present a spontaneous regression (Angelos *et al.*, 1991).

Equine sarcoid is an invasive but not metastatic neoplasia (Nasir and Reid, 1999), causing substantial morbidity and economic loss due to aesthetic and functional impairment (Angelos *et al.*, 1991; Otten *et al.*, 1993). Six different sarcoid morphotypes are known: occult, verrucous, nodular, fibroblastic, mixed and malignant (Knottenbelt, 2005). However, 84% of affected equines have more than one sarcoid morphotype (Goodrich *et al.*, 1998).

Equine sarcoids are lesions with intense fibroblastic proliferation, in which fibroblasts are disposed in fusiform bundles or spirally organized, presenting a morphology of fibropapilloma-like (Martens *et al.*, 2000). Another characteristic of this neoplasia is the presence of anaplastic and pleomorphic fibroblasts, perpendicularly orientated in relation to basal membrane, and being observed in the dermo-epidermal junction (Bogaert *et al.*, 2010). The epidermal component is only present in verrucous and mixed sarcoids (Bogaert *et al.*, 2010). The sarcoid invasiveness capability can be attributed to the high levels of expression of metalloproteinase. MMP1 promotes the laminin and collagen IV degradation, resulting in extracellular matrix remodeling (Mosseri *et al.*, 2014)

Equine sarcoid has a multifactorial cause (Bergvall, 2013). However, the *Deltapapillomavirus* is recognized as an etiological factor (Nasir and Reid, 1999; Chambers *et al.*, 2003b; Bogaert *et al.*, 2008b; Bergvall, 2013). The association between BPV and equine sarcoid was first described by Olson and Cook in 1951 (Brandt *et al.*, 2008). BPV-1 and 2 DNA sequences are identified in 100% of equine sarcoids (Martens *et al.*, 2001a; Gaynor *et al.*, 2015b). Furthermore, DNA sequences of these virus types are identified in 2/3 of asymptomatic horses (Bravo *et al.*, 2010). These data demonstrate that the virus can be asymptomatic, remaining latent in epidermis and dermis (Bogaert *et al.*, 2008b; Brandt *et al.*, 2008; Bergvall, 2013).

Viral latency is a characteristic shared by BPV (Bogaert *et al.*, 2008b; Araldi *et al.*, 2013; Silva *et al.*, 2013a) and HPV (Maran *et al.*, 1995; Astori *et al.*, 1998; Forslund *et al.*, 2004). However, the virus infection induces DNA damages and genomic instability (Stocco dos Santos, *et al.*, 1998; Melo *et al.*, 2011; Araldi *et al.*, 2013; Campos *et al.*,

2013; Melo *et al.*, 2015). Moreover, studies show that 70% of BPV-infected asymptomatic horses live in contact with cattle (Bergvall, 2013). However, although the presence of BPV-1 L1 transcripts was already verified in equine sarcoids by RT-PCR (Nasir and Reid, 1999), these neoplasias are considered abortive infection sites, since virion presence was not described. (Bogaert *et al.*, 2008b; Brandt *et al.*, 2008). The absence of productive infection in equine sarcoids suggests that the BPV cross-infection is a consequence of an erratic virus cycle (Otten *et al.*, 1993).

As verified in PB, sarcoids are frequently seen in sites most susceptible to traumatism (Angelos *et al.*, 1991; Otten *et al.*, 1993; Martens *et al.*, 2000), confirming the need of tissue micro-injury for virus infection. In addition, as in bovines, it is believed that insects can contribute to BPV transmission, because BPV-1 DNA sequences were already identified in *Musca autumnalis*, *Fannia carnicularis* and *Stomoxys calcinatrans* flies (Bergvall, 2013).

Studies also show that the Arabic breed is the most susceptible to sarcoid development (Knottenbelt, 2005; Bogaert *et al.*, 2008b). The reason for this is the presence of W3 and B1 MHC-II haplotypes that facilitate BPV infection persistence (Chambers *et al.*, 2003b; Bogaert *et al.*, 2008b).

Currently, treatments for sarcoid, as well as for PB, are almost inefficient (Bergvall, 2013). Treatment methods are: (1) surgical excision of the neoplasia, with recurrence in 50-64% of the cases within six months (Lancaster *et al.*, 1977; Martens *et al.*, 2001b; Bergvall, 2013; Mosseri *et al.*, 2014), (2) laser therapy, where recurrence is 38% (Martens *et al.*, 2001b); cryotherapy, which is inefficient for lesions larger than 2 cm² (Carr, 2009), and chemotherapy using cisplatin or 5'-fluorouracyl (5-FU), that can cause nephro and hepatotoxicity (Stewart *et al.*, 2006). The recurrence of disease is argued to be a consequence of BPV presence in the surgical margin (Martens *et al.*, 2001a). However, a current study showed a lack of correlation between BPV DNA in surgical margins and recurrence of equine sarcoids (Taylor *et al.*, 2014). Meanwhile, Brandt *et al.* (2008) identified BPV DNA sequences in peripheral blood of sarcoid-affected equines. These data suggest that, as verified in bovines (Stocco dos Santos *et al.*, 1998; Roperto *et al.*, 2011; Araldi *et al.*, 2013; Melo *et al.*, 2015), the peripheral blood can be argued as being a vehicle of viral dissemination.

Breaking paradigms

After the first reports (Campo and Jarret, 1986; Walter-Moura *et al.*, 1988), our purpose of investigation was to examine the role of peripheral blood as a potential BPV-transmitting agent. The first data came from Stocco dos Santos *et al.* (1998), which showed high levels of chromosomal aberrations in lymphocytes infected by BPV-2. That study also described the presence of BPV-2 DNA sequences in peripheral blood of donor and recipient animals and in the progeny of recipient animals. These results were

the first evidence of vertical transmission (Freitas *et al.*, 2003). In this study, we verified the presence of BPV DNA sequences and DNA damages in peripheral blood samples of animals from different areas of Brazil (Diniz *et al.*, 2009; Melo *et al.*, 2011; Araldi *et al.*, 2013). In addition, we also demonstrated the presence of different BPV types in peripheral blood and cutaneous papilloma (Araldi *et al.*, 2014a). All these data suggest a viral activity in blood cells (Stocco dos Santos *et al.*, 1998; Araldi *et al.*, 2013). The presence of BPV DNA sequences in peripheral blood mononuclear cells (PBMCs) was also described in the literature in both bovines (Roperto *et al.*, 2008; Silva *et al.*, 2013a) and equines (Brandt *et al.*, 2008, 2011), reinforcing our results. Following studies also showed the presence of BPV transcripts and the L1 capsid protein in PBMCs, demonstrating the productive infection in blood cells (Roperto *et al.*, 2011; Melo *et al.*, 2015). We also described the presence of BPV DNA sequences in different non-epithelial tissues such as spermatozoa, urine and milk (Lindsey *et al.*, 2009). These data demonstrate the need to review the natural history of papillomavirus, as currently proposed by Munday (2014).

We verified that primary culture cell lines from BPV-infected cutaneous and esophageal papilloma have chromosomal aberrations similar to those verified in peripheral blood (Campos *et al.*, 2013). In addition, using BPV-4 E7 oncoprotein transformed PALF cell lines, we demonstrated the mutagenic potential of quercetin, a flavonoid found in bracken fern *P. aquilinum*, which is recognized as a co-factor to BPV-associated upper gastric cancer (Leal *et al.*, 2003). In a current study, we also showed that the BPV induced metabolic alteration in host cells, increasing reactive oxygen species and DNA damages (Araldi, 2016; Araldi *et al.*, 2016). A summary of our main results is shown in Figure 3. These data suggest that BPV-infected cell lines are a useful model to study the pathogenic mechanisms that lead to cancer. Our contribution has allowed to know the BPV prevalence and distribution in Brazil (Diniz *et al.*, 2009; Carvalho *et al.*, 2013; Lunardi *et al.*, 2013; Melo *et al.*, 2014; Araldi *et al.*, 2014b; Cota *et al.*, 2015; Gaynor *et al.*, 2015a; Grindatto *et al.*, 2015; Dong *et al.*, 2016; Martano *et al.*, 2016). These studies showed that the co-infection of at least two BPV types is frequent (Araldi *et al.*, 2013, 2014a; Carvalho *et al.*, 2013), demonstrating the importance to develop multivalent vaccines.




Figure 3 - Evidences of BPV presence in peripheral blood and cell culture showing: A) amplicon of BPV identified using specific primers for BPV-1, 2 and 4 (Araldi *et al.*, 2013); B) BPV genome identification by chromogenic in situ hybridization (Melo *et al.*, 2015); C) BPV virions identified in cytoplasmic vesicles of PBMCs (Melo *et al.*, 2015); D) Immunodetection of BPV L1 and E2 in lymphocytes (Melo *et al.*, 2015); E) cyto-genetic aberrations (breaks) observed in BPV-infected lymphocyte (Stocco dos Santos *et al.*, 1998), F) class 2 nucleoids observed in BPV-infected lymphocytes (Araldi *et al.*, 2013); G) BPV DNA sequences identified in cell culture, using FAP59/64 degenerate primers; H) Immunodetection of BPV early proteins (E1^{E4}, E2, E7) in both oesophageal and urinary bladder carcinoma cell line (Melo *et al.*, data not published); I) BPV virion, with 55 nm, in cytoplasmic vesicle of cutaneous papilloma cell line, total magnification of 60000X (Melo *et al.*, data not published); J) bovine epithelial cell line (CRIB) treated with E6 recombinant oncoprotein showing micronucleus presence (Araldi *et al.*, 2015a); K) cyto-genetic aberration observed in BPV-infected cell line (Campos *et al.*, 2013); L) class 2 nucleoids observed in cutaneous papilloma cell line (Araldi *et al.*, data not published).

BPV-associated malignant neoplasms

Urinary bladder carcinoma

Urinary bladder carcinoma represents 0.01% of all bovine cancers (Roperto *et al.*, 2015). It is estimated that urinary bladder cancer has caused economic losses of € 4 million between 2000-2006 in the Azores (Costa and Medeiros, 2014).

The etiopathogenic role of BPV in urinary bladder carcinoma was first described in 1955 in Brazil and South Africa (Plowright, 1955). Currently, the BPV promoter action in urothelial carcinoma is well established. This is because sequences of BPV-1, 2, 13 and 14, as well as the expression of E5 oncoprotein are detected in this neoplasms (Wosiacki *et al.*, 2006; Balcos *et al.*, 2008; Roperto *et al.*, 2016; Russo *et al.*, 2016).

Urinary bladder carcinoma is clinically characterized by bovine enzootic hematuria (BHE) (Wosiacki *et al.*, 2002), which is verified in more than 90% of cattle with urinary bladder cancer (Resendes *et al.*, 2011). BHE is characterized by intermittent hematuria, which can lead to anemia and weight loss (Wosiacki *et al.*, 2002). The disease affects preferably cattle between 3-5 years old, without breed preference (Wosiacki *et al.*, 2002). BHE is associated to dietary intake of carcinogenic compounds present in *P. aquilinum*, *P. esculentum*, *P. revolution*, *Chelanthus seiberi*, *Encephalartos hildebrandti*, *Ramunaelus montana*, *R. acris*, *Climatis vitalbi* (Wosiacki *et al.*, 2002). Among these species, *P. aquilinum* stands out for its wide biogeographical distribution (Oliveira, 2012). Bracken fern is commonly observed in the South of Brazil, where there is a high incidence of BEH (Dias *et al.*, 2012).

P. aquilinum presents high levels of immunosuppressor and carcinogenic compounds, including quercetin, ptaquilosides and shikimic acid (Shahin *et al.*, 1999; Beniston *et al.*, 2001; Bonadies *et al.*, 2004). The immunosuppressor activity of these metabolites contributes to BPV infection persistence and represents an additional source of DNA mutation (Leal *et al.*, 2003). According to Tokarnia *et al.* (2000), the diary intake of 10 kg of *Pteridium* ssp. in a year can lead to BEH. Moreover, the consumption of this bracken fern can result in urinary bladder and esophageal carcinoma (Masuda *et al.*, 2011).

Therefore, BPV-1 and 2 are considered important cofactors for BEH development (Campo, 1997a; Roperto *et al.*, 2005; Pavelski *et al.*, 2014), once BPV leads to epidermal and dermal hyperproliferation at the same time that it induces DNA damages, contributing to cancer initiation (Stocco dos Santos *et al.*, 1998; Araldi *et al.*, 2013; Campos *et al.*, 2013).

Esophageal carcinoma (EC)

While the association between HPV and EC remains under discussion despite all evidences (Antonsson *et al.*, 2016), the etiological role of BPV in EC is well established

(Borzacchiello *et al.*, 2003). EC in cattle is a self-limiting disease, being directly associated to BPV-4 infection (Borzacchiello *et al.*, 2003; Masuda *et al.*, 2011).

Although there is no report about BPV transmission in humans, a study performed in Germany showed a high incidence of warts in veterinarians that had contact with bovines (Bosse and Christophers, 1964). Another study in Central Asia discussed the association between milk consumption and EC (Nasrollahzadeh *et al.*, 2015). Considering that BPV DNA sequences were already detected in milk (Lindsey *et al.*, 2009) and the thermal resistance of viral capsid (Módolo *et al.*, data not published), it seems that the virus can survive to pasteurization process (zur Hausen, 2012). Therefore, more efforts are necessary to verify this possible cross-infection.

EC is the eighth most prevalent human malignancy, being considered the sixth *causa mortis* for cancer globally (Antonsson *et al.*, 2010; Herbster *et al.*, 2012). Considered the third most common gastrointestinal cancer (Felin *et al.*, 2008), EC has a high incidence in men (Björge *et al.*, 1997). In 2002, 462,000 novel cases of EC in the world were reported (Antonsson *et al.*, 2010). Brazil had 10,780 novel cases of EC in 2014 and 7,636 deaths due to the disease in 2011 (INCA, 2016); its incidence has increased in the last years (INCA, 2016). This data leads to concern, since EC has a mortality rate that is 25% higher than cervical cancer (Han *et al.*, 1996; Kahrilas and Hirano, 2013).

Among the clinical signs of EC in humans are progressive dysphagia, weight loss, odynophagia, anorexia, fever and retrosternal pain (Felin *et al.*, 2008; Haster and Owyang, 2013), which are similar to those verified in bovines (Borzacchiello *et al.*, 2003). Scarce epidemiological data about EC in cattle are available. In humans, EC has a variable incidence according to geographic area (Björge *et al.*, 1997; Syrjänen, 2002; Guo *et al.*, 2012; Nasrollahzadeh *et al.*, 2015; Antonsson *et al.*, 2016). Among countries with high EC incidence are China, Singapore, Iran, South Africa and Brazil (Bey *et al.*, 1976; Han *et al.*, 1996; Syrjänen, 2002; Guo *et al.*, 2012). Due to the high number of EC cases in Central Asia (100/100,000) in relation to North America and Western Europe (5-10/100,000), the region is known as the Asian Esophageal Cancer Belt (Nasrollahzadeh *et al.*, 2015). Although the reason for EC incidence variation is unknown (Syrjänen, 2002; Nasrollahzadeh *et al.*, 2015), studies indicate the contribution of environmental factors, in addition to infectious agents, in the oncogenic process (Chang *et al.*, 1992; Antonsson *et al.*, 2010).

Smoking and alcohol consumption are pointed out as etiological factors for human EC (Han *et al.*, 1996; Lagergren *et al.*, 1999; Syrjänen, 2002; Haster and Owyang, 2013). However, due to sociocultural reasons, smoking does not justify the high incidence of EC in Central Asia (Nasrollahzadeh *et al.*, 2015), reinforcing the contribution of infectious agent in esophageal carcinogenesis, and evi-

dence shows the etiopathogenic contribution of different infectious agents in EC, such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex and HPV (Syrjänen, 2002).

Although the association between HPV and pre-malignant cervical lesions is known since the 1970s (Syrjänen, 2002), the participation of this virus in EC had its history marked by controversial reports in the literature (Lavergne and de Villiers, 1999). The association between HPV and EC was first proposed by Syrjänen (1982). On the one hand, HPV protein expression was observed in samples by IHC (Winkler *et al.*, 1985; Hille *et al.*, 1986; Kulski *et al.*, 1986) and viral DNA sequences were identified by CISH in EC (Chang *et al.*, 1993; Togawa *et al.*, 1994; Cooper *et al.*, 1995). On the other hand, serological studies contested these results (Dillner *et al.*, 1995; Han *et al.*, 1996; Lagergren *et al.*, 1999). However, despite these controversial results, the association between HPV and EC is currently accepted, being discussed in the 18th edition of Harrison's Principles of Internal Medicine (Kahrilas and Hirano, 2013). Thus, the absence of HPV detection by serological methods reflects a problem still observed nowadays: the use of antibodies against late (L1) proteins (Dillner *et al.*, 1995; Lagergren *et al.*, 1999). However, considering that EC does not present an HPV productive infection, the late protein expression is not expected. This occurs because HPV presents a "hit and run" mechanism (Han *et al.*, 1996; Bjørge *et al.*, 1997).

Not only serological studies are controversial. Studies based on PCR also show a low correlation between HPV and EC, mainly in clinical samples from Australia (Antonsson *et al.*, 2010; Antonsson *et al.*, 2016). These results can be attributed to the origin of clinical samples, since Australia is not considered a high-risk area for HPV-associated EC. In addition, problems involving primer sensitivity are extensively discussed in the literature of both BPV and HPV (Lavergne and de Villiers, 1999; Silva *et al.*, 2013b; de Villiers, 2013; Araldi *et al.*, 2014b). However, evidence of PVs etiopathogenic action in EC has accumulated along the last 20 years. Among these are: (1) the presence of koilocytes in EC biopsies (Bjørge *et al.*, 1997; Syrjänen, 2002; Vieira *et al.*, 2013), (2) loss or mutation in p53 as a consequence of the PV E6 oncoprotein (Chang *et al.*, 1994, 1995; Herbster *et al.*, 2012), (3) increase in telomerase activity (Syrjänen, 2002), and detection of DNA sequences of HPV-6, 11, 18, 31 and 33 in EC (Vieira *et al.*, 2013).

Prophylactic and therapeutic vaccines against BPV and HPV

Currently, there are few forms of treatment against BP available (Muro *et al.*, 2008). Among the possibilities is the papilloma surgical excision (Muro *et al.*, 2008). Although frequently employed, this method is inefficient in

cattle with high incidence of BPV, because it is impracticable to perform the excision of papillomas of all cattle. Another strategy frequently employed is self-hemotherapy (Leto *et al.*, 2011). This method consists in the removal and intramuscular reinjection of a volume of 10 mL of venous blood, inducing a nonspecific immune stimulus that can promote the "shedding of the warts" (Leto *et al.*, 2011). However, this technique does not avoid BP recurrence, thus being a palliative method. Another possibility to reduce the incidence of BP is to control ectoparasite populations, since it was demonstrated that the biological control of ticks reduces the incidence of BPV (William *et al.*, 1992).

Few medical interventions proposed in the last century can match the effects that immunization exerts on longevity (Schuchat and Jackson, 2013). For this reason, vaccination is considered the best form of prevention, control and eradication of viral etiology diseases (Ribeiro-Müller and Müller, 2014). Moreover, immunization reduces both transmission and dissemination of the infectious agent (Schuchat and Jackson, 2013).

Two prophylactic vaccines against HPV are available in the market since 2006: (1) Cervarix, produced by Glaxo-Smith Klein (GSK) and (2) Gardasil, produced by Merck (Ribeiro-Müller and Müller, 2014). These vaccines are based on virus-like particles (VLPs) of the L1 structural protein (Marigliani *et al.*, 2012). Cervarix is a bivalent vaccine able to confer protection against HPV-16 and 18, employing L1 VLPs produced in Baculovirus in *Trichoplusia ni* insect cells, using aluminum hydrophosphate as adjuvant (Ribeiro-Müller and Müller, 2014). Gardasil is able to confer protection against two high-risk HPV types (HPV-16 and 18) and two low-risk ones (HPV-6 and 11), associated to genital warts. This vaccine is composed by of L1 VLPs produced in *Saccharomyces cerevisiae*, employing lipid A 3-O-diacetate-44-monophosphoryl (ASO4) as adjuvant. Both vaccines are considered safe and well tolerated (Ribeiro-Müller and Müller, 2014). For these reasons, more than 30 countries, including Brazil, adopted immunization programs against HPV based on these vaccines.

Australia, the first country to adopt the vaccination against HPV, observed a reduction of 70% in HPV-6, 11, 16 and 18 infection incidence. Similar results were also verified in Denmark, Finland and Sweden (Ribeiro-Müller and Müller, 2014). However, available vaccines are not able to protect against all HPV types, since there are more than 200 described. Moreover, these vaccines have a high cost of production. Thus, it is necessary to invest in novel multivalent vaccines, with lower production cost. Vaccines based on recombinant protein expressed in *Escherichia coli* have demonstrated to be a useful alternative, because they have a lower cost, and not requiring the L1 VLPs, they are more stable (Ribeiro-Müller and Müller, 2014).

Although there are two vaccines against HPV, there is no vaccine yet against BPV available to date. The idea of

developing a vaccine to combat BPV began with the infection of Shope papillomas extract in the 1940 decade (Shope, 1937). Since then, different vaccine models were proposed (Jarret *et al.*, 1991; Gaukroger *et al.*, 1996; Góes *et al.*, 2008; Love *et al.*, 2012; Mazzuchelli-de-Souza *et al.*, 2013). However, none of them became a commercial product. This denotes the notorious difficulty to obtain a safe and efficient vaccine, and reflects the reduced number of research groups dedicated to develop a vaccine against BPV.

Studies have demonstrated that BPV early proteins (E6 and E7) show a therapeutic action, while later proteins (L1 and L2) have a prophylactic action (Campo, 1997b). Vaccines based on E6 and E7 have also been discussed against HPV (Borysiewicz *et al.*, 1996; He *et al.*, 2000; Yao *et al.*, 2013), reinforcing the usefulness of the BPV model not only for comprehending the pathogenic mechanisms of HPV, but also for vaccine biotechnology. However, in a current study based on BPV-1 E6 recombinant oncoprotein, we demonstrated that this oncoprotein is able to induce clastogenesis and neosis *per se* (Araldi *et al.*, 2015a). This data emphasizes the necessity of an *in silico* analysis of E6 and E7 oncoproteins, aiming to obtain novel variants that are more antigenic and less mutagenic. In order to guarantee the immunization and safety of products, our group is now focusing on the development of a prophylactic vaccine based on L1 recombinant protein (Módolo *et al.*, data not published).

Conclusions

Papillomaviridae comprises the most extensive known family of viruses, able to infect all vertebrates including humans, in which it is responsible for 27-30% of all infectious agent-associated incident cancer cases. Moreover, PVs represent an important problem in the veterinary field, inducing papillomas in dogs, felines and cattle. Also, BPV infects equines, resulting in sarcoids. Although novel discoveries contributed to the understanding of the PVs oncogenic role, some carcinogenic mechanisms remain unknown, especially those following cancer initiation (Araldi *et al.*, 2016). In addition, current studies have collected evidence of BPV productive infection in sites earlier considered as not permissive, such as PBMCs (Roperto *et al.*, 2011; Melo *et al.*, 2015), placenta (Roperto *et al.*, 2012) and primary cell cultures (Campos *et al.*, 2008; Campos *et al.*, 2013). Similar results have also been described for HPV (Chiou *et al.*, 2003; Foresta *et al.*, 2013; Pessoa, 2014). However, despite of these advances, the natural history of PVs remains dependent on cell differentiation, emphasizing the need to review the replication cycle of these viruses (White and Howley, 2013; Munday, 2014). In addition, the available vaccines against HPV do not confer protection against all virus types, providing only a limited protection. The veterinary field lives a most dramatic scene, since there is no vaccine available against BPV. Over the last 30 years,

our group has dedicated efforts to elucidate the pathogenic mechanisms of PVs, focusing on BPV, once the virus is considered a prototype for HPV studies. Although our contributions brought important advances, more studies are necessary to propose efficacious and safe prophylactic and therapeutic measures.

Dedication

This paper is dedicated to Dr. Maria Luiza Beçak on occasion of her 80th birthday. She and her husband were the founders of the Laboratory of Genetics of the Instituto Butantan, in 1961. They were Brazil's pioneers in introducing human and vertebrate cytogenetics and the first to use cytogenetics as an important tool in human genetic counseling. Dr. Beçak's contribution in classic and recent papers in the genetic literature is very important and remarkable.

Acknowledgments

The authors thank the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, process 2014/20617-5) and Fundação Butantan for the financial support.

References

- Alberti A, Pirino S, Pintore F, Addis MF, Chessa B, Cacciotto C, Cubeddu T, Anfossi A, Benenati G, Coradduzza E, *et al.* (2010) *Ovis aries* Papillomavirus 3: A prototype of a novel genus in the family Papillomaviridae associated with ovine squamous cell carcinoma. *Virology* 407:352-359.
- Alcântara B, Alfieri A, Headley S, Rodrigues W, Otonel R, Lunardi M and Alfieri A (2015) Molecular characterization of bovine Deltapapillomavirus (BPV-1, 2, and 13) DNA in equine sarcoids. *Pesqui Veterinária Bras* 35:431-436.
- Angelos J, Marti E, Lazary S and Carmichael L (1991) Characterization of BPV-like DNA in equine sarcoids. *Arch Virol* 119:95-109.
- Antonsson A, Knight L and Whiteman D (2016) Human papillomavirus not detected in esophageal adenocarcinoma tumor specimens. *Cancer Epidemiol* 41:96-98.
- Antonsson A, Nancarrow D, Brown I, Green A, Drew P, Watson D, Hayward N and Whiteman D (2010) High-risk human papillomavirus in esophageal squamous cell carcinoma. *Cancer Epidemiol Biomarkers Prev* 19:2080-2087.
- Araldi R (2015) Bovine papillomavirus: What We Know and What We Should Know. Lambert Academic Publishing, Germany, 124 p.
- Araldi R (2016) Papillomaviruses: From mutation to metastasis. 6th Euro Virology Congress and Expo, p 4172.
- Araldi R, Melo T, Diniz N, Carvalho R, Beçak W and Stocco R (2013) Bovine papillomavirus clastogenic effect analyzed in comet assay. *Biomed Res Int* 2013:1-7.
- Araldi R, Carvalho R, Melo T, Diniz N, Sant'Ana T, Mazzuchelli-de-Souza J, Spadacci-Morena D, Beçak W and Stocco R (2014a) Bovine papillomavirus in beef cattle: First description of BPV-12 and putative type BAPV8 in Brazil. *Genet Mol Res* 13:5644-5653.

- Araldi R, Giovanni D, Melo T, Diniz N, Mazzuchelli-de-Souza J, Sant'Ana T, Carvalho R, Beçak W and Stocco R (2014b) Bovine papillomavirus isolation by ultracentrifugation. *J Virol Methods* 208:119-124.
- Araldi R, Mazzuchelli-de-Souza J, Modolo D, Souza E, Melo T, Spadacci-Morena D, Magnelli R, Rocha M, De-Sá-Júnior P, Carvalho R, *et al.* (2015a) Mutagenic potential of *Bos taurus* papillomavirus type 1 E6 recombinant protein: First description. *Biomed Res Int* 2015:1-15.
- Araldi R, Melo T, Neves A, Spadacci-Morena D, Magnelli R, Módulo D, De-Sá-Júnior P, Mazzuchelli-de-Souza J, Carvalho R, Beçak W, *et al.* (2015b) Hyperproliferative action of bovine papillomavirus (BPV): Genetics and histopathological aspects. *Genet Mol Res* 14:12942-12954.
- Araldi R, Módolo D, De-Sá-Júnior P, Consonni S, Carvalho R, Roperto F, Beçak W and Stocco R (2016) Genetics and metabolic deregulation following cancer initiation: A world to explore. *Biomed Pharmacother* 82:449-458.
- Astori G, Lavergne D, Benton C, Hockmayr B, Egawa K, Garbe C and de Villiers E (1998) Human papillomavirus are commonly found in normal skin of immunocompetent hosts. *J Invest Dermatol* 110:752-55.
- Balcos L, Borzacchiello G, Russo V, Popescu O, Roperto S and Roperto F (2008) Association of bovine papillomavirus type-2 and urinary bladder tumours in cattle from Romania. *Res Vet Sci* 85:145-148.
- Beniston RG, Morgan IM, O'Brien V and Campo MS (2001) Quercetin, E7 and p53 in papillomavirus oncogenic cell transformation. *Carcinogenesis* 22:1069-1076.
- Bergvall K (2013) Sarcoids. *Vet Clin Equine* 29:657-671.
- Bernard H (1994) Coevolution of papillomaviruses with human populations. *Trends Microbiol* 2:18-21.
- Bernard H, Calleja-Macias I and Dunn S (2006) Genome variation of human papillomavirus types: Phylogenetic and medical implications. *Int J Cancer* 118:1071-1076.
- Bey E, Alexander J, Whitcutt J, Hunt J and Gear J (1976) Carcinoma of the esophagus in Africans: Establishment of a continuously growing cell line from a tumor specimen. *In Vitro* 12:107-114.
- Bjørge T, Hakulinen T, Engeland A, Jellum E, Koskel P, Lehtinen M, Luostarinen T, Paavonen J, Sapp M, Schiller J, *et al.* (1997) A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. *Cancer Res* 57:3989-3992.
- Black P (1968) The oncogenic DNA viruses: A review of in vitro transformation studies. *Annu Rev Microbiol* 22:391-426.
- Bocaneti F, Altamura G, Corteggio A, Velescu E, Roperto F and Borzacchiello G (2014) Bovine papillomavirus: New insights into an old disease. *Transbound Emerg Dis* 63:1-10.
- Bogaert L, Martens A, Van Poucke M, Ducatelle R, De Cock H, Dewulf J, De Baere C, Peelman L and Gasthuys F (2008a) High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. *Vet Microbiol* 129:58-68.
- Bogaert L, Martens A, Kast W, Van Marck E and De Cock H (2010) Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors. *Vet Microbiol* 146:269-275.
- Bogaert L, Martens A, Van Poucke M, Ducatelle R, De Cock H, Dewulf J, De Baere C, Peelman L and Gasthuys F (2008b) High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. *Vet Microbiol* 129:58-68.
- Bonadies F, Borzacchiello G, Dezzi S, Nicoletti R and Roperto S (2004) Mass spectrometric analysis of ptaquiloside, the toxic sesquiterpene from bracken fern. *Rapid Commun Mass Spectrometry* 18:825-828.
- Boon S, Tomaic V, Thomas M, Roberts S and Banks L (2015) Cancer-causing human papillomavirus E6 proteins display major differences in the phospho-regulation of their PDZ interactions. *J Virol* 89:1579-1586.
- Börkú M, Atalay O, Kibar M, Cam Y and Atasever A (2007) Ivermectin is an effective treatment for bovine cutaneous papillomatosis. *Res Vet Sci* 83:360-363.
- Borysiewicz L, Fiander A, Nimako M, Man S, Wilkinson G, Westmoreland D, Evans A, Adams M, Stacey S, Bourns M, *et al.* (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. *Lancet* 347:1523-1527.
- Borzacchiello G (2007) Bovine papillomavirus infections in animals. *Commun Curr Res Educ Top Trends Appl Microbiol* 673-679.
- Borzacchiello G, Ambrosio V, Roperto S, Poggiali F, Tsimonakis E, Venuti A, Campo M and Roperto F (2003) Bovine papillomavirus type 4 in oesophageal papillomas of cattle from the South of Italy. *J Comp Pathol* 128:203-206.
- Borzacchiello G and Roperto F (2008) Bovine papillomaviruses, papillomas and cancer in cattle. *Vet Res* 39:45.
- Bosse K and Christophers E (1964) Beitrag zur Epidemiologie der Warzen. *Hautarzt* 15:80.
- Boulet G, Horvath C, Vanden B, Sahebali S and Bogers J (2007) Human papillomavirus: E6 and E7 oncogenes. *Int J Biochem Cell Biol* 39:2006-2011.
- Brandt S, Haralampus R, Schoster A, Kirnbauer R and Stanek C (2008) Peripheral blood mononuclear cells represent a reservoir of bovine papillomavirus DNA in sarcoid-affected equines. *J Gen Virol* 89:1390-1395.
- Brandt S, Schoster A, Tober R, Kainzbauer C, Burgstaller JP, Haralampus R, Steinborn R, Hinterhofer C and Stanek C (2011) Consistent detection of bovine papillomavirus in lesions, intact skin and peripheral blood mononuclear cells of horses affected by hoof canker. *Equine Vet J* 43:202-209.
- Bravo I and Felez-Sanchez M (2015) Papillomaviruses: Viral evolution, cancer and evolutionary medicine. *Evol Med Public Health* 2015:32-51.
- Bravo I, Sanjosé S and Gottschling M (2010) The clinical importance of understanding the evolution of papillomaviruses. *Trends Microbiol* 18:432-438.
- Brobst D and Hinsman E (1966) Electron microscopy of the bovine cutaneous papilloma. *Vet Pathol* 3:196-207.
- Brücher B and Jamall I (2014) Epistemology of the origin of cancer: A new paradigm. *BMC Cancer* 15:1-15.
- Buck C, Day P and Trus B (2013) The papillomavirus major capsid protein L1. *Virology* 445:169-174.
- Buck C, Pastrana D, Lowy D and Schiller J (2004) Efficient intracellular assembly of papillomaviral vectors. *J Virol* 78:751.
- Burkhardt A, Willingham M, Gay C, Jeang K and Schlegel R (1989) The E5 oncoprotein of bovine papillomavirus is oriented asymmetrically in Golgi and plasma membranes. *Virology* 339:334-339.

- Burnett S, Jareborg N and Dimaiot D (1992) Localization of bovine papillomavirus type 1 E5 protein to transformed basal keratinocytes and permissive differentiated cells in fibropapilloma tissue. *Proc Natl Acad Sci U S A* 89:5665-5669.
- Cai Q, Lv L, Shao Q, Li X and Dian A (2013) Human papillomavirus early proteins and apoptosis. *Arch Gynecol Obstet* 287:541-548.
- Campo M (1997a) Bovine papillomavirus and cancer. *Vet J* 154:175-188.
- Campo M (1997b) Vaccination against papillomavirus in cattle. *Clin Dermatol* 15:275-283.
- Campo M (2002) Animal models of papilloma virus pathogenesis. *Virus Res* 89:249-261.
- Campo M (2006) Bovine papillomavirus: Old system, new lessons? *Papillomavirus research: From natural history to vaccine and beyond*. Caister Academic Press, Norfolk, pp 373-387.
- Campo M and Jarret WF (1986) Papillomavirus infection in cattle: Viral and chemical cofactors in naturally occurring and experimentally induced tumours. *Ciba Found Symp* 120:117-135.
- Campos S, Trindade C, Ferraz O, Giovanni D, Lima A, Caetano HA, Carvalho R, Birgel E, Dagli M, Mori E, *et al.* (2008) Can established cultured papilloma cells harbor bovine papillomavirus? *Genet Mol Res* 7:1119-1126.
- Campos S, Melo T, Assaf S, Araldi R, Mazzuchelli-de-Souza J, Sircili M, Carvalho R, Roperto F, Beçak W and Stocco R (2013) Chromosome aberrations in cells infected with bovine papillomavirus: Comparing cutaneous papilloma, esophagus papilloma, and urinary bladder lesion cells. *ISRN Oncol* 2013:910849.
- Carr E (2009) New developments in diagnosis and treatment of equine sarcoids. In: Robinson N and Sprayberry K (eds) *Current Therapy in Equine Medicine*. 6th ed. Saunders Elsevier, St. Louis, pp 698-705.
- Carvalho R, Sakata S, Giovanni D, Mori E, Brandão P, Richtzenhain L, Pozzi C, Arcaro J, Miranda M, Mazzuchelli-de-Souza J, *et al.* (2013) Bovine papillomavirus in Brazil: Detection of coinfection of unusual types by a PCR-RFLP method. *Biomed Res Int* 2013:270898.
- Catrox M, Martins A, Petrella S, Souza F and Nastari B (2013) Ultrastructural study of bovine papillomavirus during outbreaks in Brazil. *Int J Morphol* 31:777-784.
- Chambers G, Ellsmore V, O'Brien P, Reid S, Love S, Campo M and Nasir L (2003a) Sequence variants of bovine papillomavirus E5 detected in equine sarcoids. *Virus Res* 96:141-145.
- Chambers G, Ellsmore V, O'Brien P, Reid S, Love S, Campo M and Nasir L (2003b) Association of bovine papillomavirus with the equine sarcoid. *J Gen Virol* 84:1055-1062.
- Chang F, Syrjanen S, Wang L and Syrjanen K (1992) Infectious agents in the etiology of esophageal cancer. *Gastroenterology* 103:1336-1348.
- Chang F, Syrjanen S, Shen Q, Wang L and Syrjanen K (1993) Screening for human papillomavirus infections in esophageal squamous cell carcinomas by in situ hybridization. *Cancer* 72:2525-2530.
- Chang F, Syrjanen S, Tervahauta A, Kurvinen K, Wang L and Syrjanen K (1994) Frequent mutations of p53 gene in oesophageal squamous cell carcinomas with and without human papillomavirus (HPV) involvement suggest the dominant role of environmental carcinogens in oesophageal carcinogenesis. *Br J Cancer* 70:346-351.
- Chang F, Syrjanen S and Syrjanen K (1995) Implications of the p53 tumor-suppressor gene in clinical oncology. *J Clin Oncol* 13:1009-1022.
- Chen J, Hong Y and Androphy E (1997) Mutational analysis of transcriptional activation by the bovine papillomavirus type 1 E6. *Virology* 236:30-36.
- Chen P and Lee H (2015) FOXM1 induced by E6 oncoprotein promotes tumor invasion and chemoresistance in HPV-infected lung cancer. *Cancer Cell Microenviron* 2:6-9.
- Chiou H, Wu M, Liaw Y, Cheng Y, Wong R, Chen C and Lee H (2003) The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. *Cancer* 97:1558-1563.
- Chowdhury D, Keogh M, Ishii H, Peterson C, Buratowski S and Lieberman J (2005) gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. *Mol Cell* 20:801-809.
- Claus M, Vivian D, Lunardi M, Alfieri A and Alfieri A (2007) Análise filogenética de papilomavírus bovino associado com lesões cutâneas em rebanhos do Estado do Paraná. *Pesqui Veterinária Bras* 27:314-318.
- Claus M, Lunardi M, Alfieri A, Sartori D, Fungaro H and Alfieri A (2009) Identification of the recently described new type of bovine papillomavirus (BPV-8) in a Brazilian beef cattle herd. *Pesqui Veterinária Bras* 29:25-28.
- Cooper K, Taylor L and Govind S (1995) Human papillomavirus DNA in oesophageal carcinomas in South Africa. *J Pathol* 175:273-277.
- Costa R and Medeiros R (2014) Bovine papillomavirus: Opening new trends for comparative pathology. *Arch Virol* 159:191-198.
- Cota J, Peleteiro M, Petti L, Tavares L and Duarte A (2015a) Detection and quantification of bovine papillomavirus type 2 in urinary bladders and lymph nodes in cases of bovine enzootic hematuria from the endemic region of Azores. *Vet Microbiol* 178:138-143.
- Cotchin E (1962) Problems of comparative oncology. *Vet Pathol* 26:633-648.
- Cotchin E (1976) Comparative oncology: The veterinary contribution. *Proc R Soc Med* 69:649-656.
- Cubie H (2013) Diseases associated with human papillomavirus infection. *Virology* 445:21-34.
- Cunningham S, Jackson R and Zehbe I (2014) Hypoxia-inducible factor 1 and its role in viral carcinogenesis. *Virology* 456-457:370-383.
- Danos O, Georges E, Orth G and Yaniv M (1985) Fine structure of the cottontail rabbit papillomavirus mRNAs expressed in the transplantable VX2 carcinoma. *J Virol* 53:735-741.
- Day P, Lowy D and Schiller J (2003) Papillomaviruses infect cells via a clathrin-dependent pathway. *Virology* 307:1-11.
- de Villiers E (2013) Cross-roads in the classification of papillomaviruses. *Virology* 445:2-10.
- de Villiers E, Fauquet C, Broker T, Bernard H and zur Hausen H (2004) Classification of papillomaviruses. *Virology* 324:17-27.
- Dias J, Ignacchiti M, Giuriato P, Nunes L and Pereira-Júnior O (2012) Detecção do papilomavírus bovino tipo 2 em bexigas de bovinos com hematúria enzoótica pela técnica de reação

- em cadeia de polimerase no Sul do Espírito Santo, Brasil. *Rev Bras Med Veterinária* 34:146-151.
- Dillner J, Knekt P, Schiller J and Hakulinen T (1995) Prospective seroepidemiological evidence that human papillomavirus type 16 infection is a risk factor for oesophageal squamous cell carcinoma. *BMJ* 311:1346.
- DiMaio D (2014) Viral miniproteins. *Annu Rev Microbiol* 68:21-43.
- Diniz N, Melo T, Santos J, Mori E, Brandão P, Richtzenhain L, Freitas A, Beçak W, Carvalho R and Stocco R (2009) Simultaneous presence of bovine papillomavirus in blood and in short-term lymphocyte cultures from dairy cattle in Pernambuco, Brazil. *Genet Mol Res* 8:1474-1480.
- Dong J, Zhu W and Haga T (2016) Papillomavirus in yaks: The isolates of bovine papillomavirus type 1 have a high possibility of belonging to novel type. *J Vet Med Sci* 78:1059-1061.
- Doorbar J (2013) The E4 protein; structure, function and patterns of expression. *Virology* 445:80-98.
- Elzein E, Sundberg J, Housawi F, Gameel A, Ramadan R and Hassanein M (1991) Genital bovine papillomavirus infection in Saudi Arabia. *J Vet Diagnostic Investig* 3:36-38.
- Enemark E, Chen G, Vaughn D, Stenlund A, Joshua-Tor L, Brook S and York N (2000) Crystal structure of the DNA binding domain of the replication initiation protein E1 from papillomavirus. *Mol Cell* 6:149-158.
- Felin I, Grivicich I, Felin C, Regner A and Rocha A (2008) Expressão de p53, p16 e COX-2 em carcinoma escamoso de esôfago e associação histopatológica. *Arq Gastroenterol* 45:308-312.
- Ferraro C, Canedo M, Oliveira S, Carvalho M and Dias E (2011) Infecção oral pelo HPV e lesões epiteliais proliferativas associadas. *J Bras Patol Médica e Lab* 47:451-459.
- Finlay M, Yuan Z, Burden F, Trawford A, Morgan I, Campo M and Nasir L (2009) The detection of bovine papillomavirus type 1 DNA flies. *Virus Res* 144:315-317.
- Florin L, Sapp M and Spoden G (2012) Host-cell factors involved in papillomavirus entry. *Med Microbiol Immunol* 201:437-448.
- Foresta C, Bertoldo A, Garolla A, Pizzol D, Mason S, Lenzi A and De Toni L (2013) Human papillomavirus proteins are found in peripheral blood and semen Cd20+ and Cd56+ cells during Hpv-16 semen infection. *BMC Infectious Dis* 13:e593.
- Forslund O, Antonsson A, Nordin P, Stenquist B and Hansson BG (1999) A broad range of human papillomavirus types detected with a general PCR method suitable for analysis of cutaneous tumours and normal skin. *J Gen Virol* 80:2437-2443.
- Forslund O, Lidelof B, Hrail E, Norin P, Stenquist B, Kimbauer P, Slutzky K and Dillner J (2004) High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "stripped" biopsies from the same tumors. *J Invest Dermatol* 123:388-394.
- Freitas AC De, Carvalho C De, Brunner O, Birgel-Junior EH, Maria A, Paiva M, Benesi FJ, Gregory L, Beçak W and De Cassia R (2003) Viral DNA sequences in peripheral blood and vertical transmission of the virus: A discussion about BPV-1. *Braz J Microbiol* 34:76-78.
- García-Vallvé S, Alonso A and Bravo I (2005) Papillomaviruses: Different genes have different histories. *Trends Microbiol* 13:514-521.
- Gaukroger JM, Chandrachud LM, O'Neil BW, Grindlay GJ, Knowles G and Campo MS (1996) Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. *J Gen Virol* 77:1577-1583.
- Gauson E, Wang X, Dornan E, Herzyk P, Bristol M and Morgan I (2016) Failure to interact with Brd4 alters the ability of HPV16 E2 to regulate host genome expression and cellular movement. *Virus Res* 211:1-8.
- Gaynor A, Fish S, Duerr R, Cruz F and Pesavento P (2015a) Identification of a novel papillomavirus in a Northern Fulmar (*Fulmarus glacialis*) with viral production in cartilage. *Vet Pathol* 52:553-561.
- Gaynor A, Zhu K, Cruz F, Affolter V and Pesavento P (2015b) Localization of bovine papillomavirus nucleic acid in equine sarcoids. *Vet Pathol* 53:567-573.
- Geisshüsler H, Marti E, Stoffel M, Kühni K, Stojiljkovic A, von Tscherner C, Vidondo B, Gerber V and Koch C (2016) Quantitative analysis of infiltrating immune cells and bovine papillomavirus type 1 E2-positive cells in equine sarcoids. *Vet J* 216:45-52.
- Góes L, Freitas A, Ferraz O, Rieger T, Santosa J, Pereira A, Beçak W, Lindsey C and Stocco R (2008) Bovine papillomavirus type 4 L1 gene transfection in a *Drosophila* S2 cell expression system: Absence of L1 protein expression. *Braz J Microbiol* 39:1-4.
- Goodrich L, Gerber H, Marti E and Antczak D (1998) Equine sarcoids. *Vet Clin North Am Equine Pract* 14:607-623.
- Gopalkrishna V, Srivastava A, Hedau S, Sharma J and Das B (1995) Detection of human papillomavirus DNA sequences in cancer of the urinary bladder by *in situ* hybridisation and polymerase chain reaction. *Sex Transm Infect* 71:231-233.
- Gottschling M, Stamatakis A, Nindl I, Stockfleth E, Alonso A and Bravo I (2007) Multiple evolutionary mechanisms drive papillomavirus diversification. *Mol Biol Evol* 24:1242-1258.
- Gottschling M, Goker M, Stamatakis A, Bininda-Emonds O, Nindl I and Bravo I (2011) Quantifying the phylogenetic forces driving papillomavirus evolution. *Mol Biol Evol* 28:2101-2113.
- Graner J (2000) History of infectious diseases oncology, from Galen to Rous. In: Goedert JJ (ed) *Infectious Causes of Cancer*. Humana Press, Nova Jersey, pp 3-30.
- Greber U (2016) Virus and host mechanics support membrane penetration and cell entry. *J Virol* 90: 3802-3805.
- Green M (1972) Molecular basis for the attack on cancer. *Proc Natl Acad Sci U S A* 69:1036-1041.
- Grindatto A, Ferraro G, Varello K, Crescio M, Miceli I, Bozzetta E, Gorla M and Nappi R (2015) Molecular and histological characterization of bovine papillomavirus in North West Italy. *Vet Microbiol* 180:113-117.
- Guo F, Liu Y, Wang X, He Z, Weiss N, Madeleine M, Liu F, Tian X, Song Y, Pan Y, *et al.* (2012) Human papillomavirus infection and esophageal squamous cell carcinoma: A case-control study. *Cancer Epidemiol Biomarkers Prev* 21:780-785.
- Haga T, Dong J, Zhu W and Burk R (2013) The many unknown aspects of bovine papillomavirus diversity, infection and pathogenesis. *Vet J* 197:122-123.
- Han C, Qiao G, Hubbert N, Li L, Sun C, Wang Y, Yan M, Xu D, Li Y, Lowy D, *et al.* (1996) Serologic association between human papillomavirus type 16 infection and esophageal

- cancer in Shaanxi Province, China. *J Natl Cancer Inst* 88:1467-1471.
- Handisurya A, Day P, Thompson C, Buck C, Pang Y, Lowy D and Schiller J (2013) Characterization of *Mus musculus* papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization. *J Virol* 87:13214-25.
- Hansen T, Fridholm H, Frøslev T, Kjartansdóttir K, Willerslev E, Nielsen L and Hansen A (2015) New type of papillomavirus and novel circular single stranded DNA virus discovered in urban *Rattus norvegicus* using circular DNA enrichment and metagenomics. *PLoS One* 10:e0141952.
- Hartl B, Hainisch E, Shafti-Keramat S, Kimbauer R, Corteggio A, Borzacchiello G, Tober R, Kainzbauer C, Pratscher B and Brandt S (2011) Inoculation of young horses with bovine papillomavirus type 1 virions leads to early infection of PBMCs prior to pseudo-sarcomatous formation. *J Gen Virol* 92:2437-2445.
- Haster W and Owyang C (2013) Abordagem do paciente com doença gastrointestinal. In: Longo D, Kasper D, Jamenson J, Fauci A, Hauser D and Loscalzo J (eds) *Medicina Interna de Harrison*. 18^a ed. Artmed, Porto Alegre, pp 2402-2426.
- Hatama S, Nobumoto K and Kanno T (2008) Genomic and phylogenetic analysis of two novel bovine papillomaviruses, BPV-9 and BPV-10. *J Gen Virol* 89:158-163.
- He Z, Meng Q, Qiao J, Peng Y, Xie K, Liu Y, Cai X, Zhang J and Chen C (2014) Mixed nipple infections caused by variant of BPV3 and a putative new subtype of BPV in cattle. *Transbound Emerg Dis* 63:e140-143.
- He Z, Wlazlo A, Kowalczyk D, Cheng J, Xiang Z, Giles-Davis W and Ertl H (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. *Virology* 270:146-161.
- Helfer C, Yan J and You J (2014) The cellular bromodomain protein Brd4 has multiple functions in E2-mediated papillomavirus transcription activation. *Viruses* 6:3228-3249.
- Hennessy B, Smith D, Ram P, Lu Y and Mills G (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 4:988-1004.
- Herbster S, Ferraro C, Koff N, Rossini A, Krueger C, Andreollo N, Rapozo D, Blanco T, Faria P, Santos P, *et al.* (2012) HPV infection in Brazilian patients with esophageal squamous cell carcinoma: Interpopulational differences, lack of correlation with surrogate markers and clinicopathological parameters. *Cancer Lett* 326:52-58.
- Hille J, Margolius K, Markowitz S and Isaacson C (1986) Human papillomavirus infection related to oesophageal carcinoma in black South Africans. *South Africa Med J* 69:417-420.
- Holland J and Domingo E (1998) Origin and evolution of viruses. *Virus Genes* 16:13-21.
- INCA (Instituto Nacional de Câncer) (2016) Estimativa 2016. Ministério da Saúde/Inst Nac Cancer José Alencar Gomes da Silva, Rio de Janeiro, 122 p.
- Jackson C (1936) The incidence and pathology of tumours of domestic animals in South Africa. Onderstepoort *J Vet Sci Anim Ind* 6:378-385.
- Jang M, Shen K and McBride A (2014) Papillomavirus genomes associate with BRD4 to replicate at fragile sites in the host genome. *PLoS Pathog* 10:e1004117.
- Jarret W, Smith K, O'Neil B, Gaukroger J, Chandrachud L, Grindlay G, McGarvie G and Campo M (1991) Studies on vaccination against Papillomavirus: Prophylactic and therapeutic vaccination with recombinant structural proteins. *Virology* 184:2-42.
- Kahrilas P and Hirano E (2013) Doenças do esôfago. In: Longo D, Kasper D, Jamenson J, Fauci A, Hauser S and Loscalzo J (eds) *Medicina Interna de Harrison*. 18^a ed. Artmed, Porto Alegre, pp 2437-37.
- Kawauchi K, Takahashi C, Ishihara R and Hatama S (2015) Development of a novel PCR-RFLP assay for improved detection and typing of bovine papillomaviruses. *J Virol Methods* 218:23-26.
- Kines R, Cerio R, Roberts J, Thompson C, Pinos E, Lowy D and Schiller J (2016) Human papillomavirus capsids preferentially bind and infect tumor cells. *Int J Cancer* 138:901-911.
- Knottenbelt D (2005) A suggested clinical classification for the equine sarcoid. *Clin Tech Equine Pract* 4:278-295.
- Koller L and Olson C (1972) Attempted transmission of warts from man, cattle, and horses and of deer fibroma, to selected hosts. *J Invest Dermatol* 58:366-368.
- Král J, Band'ouchová H, Brichta J, Kováčová V, Ondráček K, Osicková J, Hrubá H, Hutarová Z, Komínková M, Cernei N, *et al.* (2015) Papillomavirus infection of roe deer in the Czech Republic and fibropapilloma-associated levels of metallothionein, zinc and oxidative stress. *Acta Vet Brno* 84:105-111.
- Krawczyk E, Suprynowicz F, Liu X, Dai Y, Hartmann D, Hanover J and Schlegel R (2008) Koilocytosis: A cooperative interaction between the human papillomavirus. *Am J Pathol* 173:682-688.
- Krawczyk E, Suprynowicz F, Sudarshan S and Schlegel R (2010) Membrane orientation of the human papillomavirus type 16 E5 oncoprotein. *J Virol* 84:1696.
- Kulski J, Demeter T, Sterrett G and KB S (1986) Human papilloma virus DNA in oesophageal carcinoma. *Lancet* 2:683-684.
- Lagergren J, Wang Z, Bergstrom R, Dillner J and Nyre O (1999) Human papillomavirus infection and esophageal cancer: A nationwide seroepidemiologic case-control study in Sweden. *J Natl Cancer Inst* 91:156-162.
- Lancaster WD, Olson C and Meinke W (1977) Bovine papilloma virus: Presence of virus-specific DNA sequences in naturally occurring equine tumors. *Proc Natl Acad Sci USA* 74:524-528.
- Lavergne D and de Villiers E (1999) Papillomavirus in esophageal papillomas and carcinomas. *Int J Cancer* 80:681-684.
- Leal A, Ferraz O, Carvalho C, Freitas A, Beniston R, Beçak W, Campo M and Stocco dos Santos R (2003) Quercetin induces structural chromosomal aberrations and uncommon rearrangements in bovine cells transformed by the E7 protein of bovine papillomavirus type 4. *Vet Comp Oncol* 1:15-21.
- Leatherwood J (1998) Emerging mechanisms of eukaryotic DNA replication initiation. *Curr Opin Cell Biol* 10:742-748.
- Leto M, Santos-Júnior G, Porro A and Tomimori J (2011) Human papillomavirus infection?: Etiopathogenesis, molecular biology and clinical manifestations. *An Bras Dermatol* 86:306-317.
- Lindsey C, Almeida M, Vicari C, Carvalho C, Yagui A, Freitas A, Beçak W and Stocco R (2009) Bovine papillomavirus DNA in milk, blood, urine, semen, and spermatozoa of bovine papillomavirus-infected animals. *Genet Mol Res* 8:310-318.

- Lioi MB, Barbieri R, Borzacchiello G, Dezzi S, Roperto S, Santoro A, Russo V and Roperto F (2004) Chromosome aberrations in cattle with chronic enzootic haematuria. *J Comp Pathol* 131:233-236.
- Liu Y and Baleja J (2008) Structure and function of the papillomavirus E6 protein and its interacting proteins. *Front Biosci* 1:121-134.
- Liu Y, Liu Z, Gao H, Zhou Y, Androphy E and Chen J (2005) Opposing effects of bovine papillomavirus type 1 E6 and E7 genes on Fas-mediated apoptosis. *Oncogene* 24:3942-3953.
- Liu Z, Liu Y, Hong Y, Rapp L, Androphy E and Chen J (2002) Bovine papillomavirus type 1 E6-induced sensitization to apoptosis is distinct from its transforming activity. *Virology* 295:230-237.
- Ljubojevic S and Skerlev M (2014) HPV-associated diseases. *Clin Dermatol* 32:227-234.
- Longo D (2013) Biologia celular e angiogênese do câncer. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J (eds) *Medicina Interna de Harrison*. 18^a ed. Artmed, Porto Alegre, pp 672-688.
- Longworth M and Laimins L (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. *Microbiol Mol Biol Rev* 68:362-372.
- Love A, Chapman S, Matic S, Noris E, Lomonossoff G and Taliansky M (2012) In planta production of a candidate vaccine against bovine papillomavirus type 1. *Planta* 236:1305-1313.
- Lucena R, Rissi D, Kommers G, Pierezan F, Oliveira-Filho J, Macêdo J, Flores M and Barros C (2011) A retrospective study of 586 tumours in Brazilian cattle. *J Comp Pathol* 145:20-24.
- Lunardi M, Alcântara B, Otonel R, Rodrigues W, Alfieri A and Alfieri A (2013) Bovine papillomavirus type 13 DNA in equine sarcoids. *J Clin Microbiol* 51:2167-2171.
- Maiolino P, Ozkul A, Sepici-Dincel A, Roperto F, Yücel G, Russo V, Urraro C, Lucà R, Riccardi M, Martano M, *et al.* (2013) Bovine papillomavirus type 2 infection and microscopic patterns of urothelial tumors of the urinary bladder in water buffalo. *Biomed Res Int* 2013:937918.
- Maran A, Amella C, Dilorenzo T, Auburn K, Taichman L and Steinberg B (1995) Human papillomavirus type-11 transcripts are present at low abundance in latently infected respiratory tissue. *Virology* 212:285-294.
- Marigliani B, Kavati EA, Sakauchi D, Oliveira H, Canali R and Sasaki A (2012) Intracellular distribution of recombinant human papillomavirus capsid proteins. *Curr Micros Contrib Adv Sci Technol* 678-684.
- Marrazzo J and Holmes K (2013) Infecções sexualmente transmissíveis: Considerações gerais e abordagem clínica. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J (eds) *Medicina Interna de Harrison*. 18^a ed. Artmed, Porto Alegre, pp 1095-1111.
- Martano M, Corteggio A, Restucci B, Biase M, Borzacchiello G and Maiolino P (2016) Extracellular matrix remodeling in equine sarcoid: An immunohistochemical and molecular study. *BMC Vet Res* 12:e24.
- Martelli-Marzagão F, Yamashiro A, Ogawa M, Santos-Júnior G, Tomimori J and Porro A (2010) Caracterização clínica e histopatológica e tipagem do papilomavírus humano das verrugas vulgares nos receptores de transplante renal. *An Bras Dermatol* 85:743-746.
- Martens A, De Moor A, Demeulemeester J and Ducatelle R (2000) Histopathological characteristics of five clinical types of equine sarcoid. *Res Vet Sci* 69:295-300.
- Martens A, De Moor A and Ducatelle R (2001a) PCR detection of bovine papilloma virus DNA in superficial swabs and scrapings from equine sarcoids. *Vet J* 161:280-286.
- Martens A, De Moor A, Vlamincx L, Pille F and Steenhaut M (2001b) Evaluation of excision, cryosurgery and local BCG vaccination for the treatment of equine sarcoids. *Vet Rec* 49:665-669.
- Masuda E, Kommers G, Rosa F, Barros C, Figuera R and Piazer J (2011) Relação entre a linfopenia e a persistência da papilomatose alimentar em bovinos intoxicados crônica e espontaneamente por samambaia (*Pteridium aquilinum*). *Pesqui Vet Bras* 31:383-388.
- Mazzuchelli-de-Souza J, Carvalho R, Ruiz R, Melo T, Araldi R, Carvalho E, Thompson C, Sircili M, Beçak W and Stocco R (2013) Expression and in silico analysis of the recombinant bovine papillomavirus E6 protein as a model for viral oncoproteins studies. *Biomed Res Int* 2013:421398.
- Melo TC, Diniz N, Campos SRC, Ferraz OP, Lindsey CJ, Rieger TT, Beçak W and Stocco RC (2011) Cytogenetic studies in peripheral blood of bovines afflicted by papillomatosis. *Vet Comp Oncol* 9:269-274.
- Melo T, Carvalho R, Mazzuchelli-de-Souza J, Diniz N, Vasconcelos S, Assaf S, Araldi R, Ruiz R, Kerkis I, Beçak W, *et al.* (2014) Phylogenetic classification and clinical aspects of a new putative Deltapapillomavirus associated with skin lesions in cattle. *Genet Mol Res* 13:2458-2469.
- Melo T, Araldi R, Pessoa N, De-Sá-Júnior P, Carvalho R, Beçak W and Stocco (2015) *Bos taurus* papillomavirus activity in peripheral blood mononuclear cells?: Demonstrating a productive infection. *Genet Mol Res* 14:16712-16727.
- Mischo A, Ohlenschläger O, Hortschansky P, Ramachandran R and Görlach M (2013) Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain. *PLoS One* 8:e6284.
- Misdorp W (1996) Veterinary cancer epidemiology. *Vet Q* 18:32-36.
- Monte T and Peixoto G (2010) A incidência de papilomavírus humano em mulheres no Hospital Universitário Sul Fluminense. *Rev Bras Análises Clínicas* 42:131-139.
- Monteiro V, Coelho M, Carneiro A, Silva R, Teixeira M, Wanderley A, Wanderley E and Franco E (2008) Descrição clínica e histopatológica da papilomatose cutânea bovina (BPV). *Ciênc Anim Bras* 10:550-560.
- Moody C and Laimins L (2010) Human papillomavirus oncoproteins: Pathways to transformation. *Nat Rev Cancer* 10:550-560.
- Mosseri S, Hetzel U, Hahn S, Michaloupoulou E, Sallabank H, Knottenbelt D and Kipar A (2014) Equine sarcoid: In situ demonstration of matrix metalloproteinase expression. *Vet J* 202:279-285.
- Munday J (2014) Bovine and human papillomaviruses: A comparative review. *Vet Pathol* 51:1063-1075.
- Munday J, Thomson N, Dunowska M, Knight C, Laurie R and Hills S (2015) Genomic characterisation of the feline sarcoid-associated papillomavirus and proposed classification as *Bos taurus* papillomavirus type 14. *Vet Microbiol* 177:289-295.

- Muro L, Botteira C and Piccinin A (2008) Papilomatose bovina. *Rev Cient Eletr Med Vet* 10.
- Nasir L and Campo M (2008) Bovine papillomaviruses: Their role in the aetiology of cutaneous tumours of bovinds and equids. *Vet Dermatol* 19:243-254.
- Nasir L and Reid S (1999) Bovine papillomaviral gene expression in equine sarcoid tumours. *Virus Res* 61:171-175.
- Ng T, Miller M, Kondov N, Dodd E, Batac F, Manzer M, Ives S, Saliki J, Deng X and Delwart E (2015) Oral papillomatosis caused by *Enhydra lutris papillomavirus 1* (EIPV-1) in southern sea otters (*Enhydra lutris nereis*) in California, USA. *J Wildl Dis* 51:446-453.
- Nasrollahzadeh D, Ye W, Shakeri R, Sotoudeh M, Merat S, Kamangar F, Abnet C, Islami F, Boffetta P, Dawsey S, *et al.* (2015) Contact with ruminants is associated with esophageal squamous cell carcinoma risk. *Int J Cancer* 136:1468-1474.
- Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW and Stanley MA (2001). Regression of canine papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. *Virology* 283:31-39.
- Nicolas G, Pottier C, Maltête D, Coutant S, Rovelet-Lecrux A, Legallic S, Rousseau S, Vaschalde Y, Guyant-Maréchal L, Augustin J, *et al.* (2013) Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. *Neurology* 80:181-187.
- Nominé Y, Masson M, Charbonnier S, Zanier K, Ristriani T, Deryckère F, Sibler A, Desplancq D, Atkinson R, Weiss E, *et al.* (2006) Structural and functional analysis of E6 oncoprotein: Insights in the molecular pathways of human papillomavirus-mediated pathogenesis. *Mol Cell* 21:665-678.
- Moreno-Lopez J, Ahola H, Stenlund A, Osterhaus A and Pettersson U (1984) Genome of an avian papillomavirus. *J Virol* 51:872-875.
- Ogawa T, Tomita Y, Okada M, Shinozaki K, Kubonoya H, Kaiho I and Shirasawa H (2004) Broad-spectrum detection of papillomaviruses in bovine teat papillomas and healthy teat skin. *J Gen Virol* 85:2191-2197.
- Oliveira R (2012) Studies on the Biopathological Actions of *Pteridium aquilinum*. Universidade do Porto, Porto, 150 p.
- Otten N, von Tscharnher C, Lazary S, Antczak D and Gerber H (1993) DNA of bovine papillomavirus type 1 and 2 in equine sarcoids: PCR detection and direct sequencing. *Arch Virol* 132:121-131.
- Özsoy S, Özyildiz Z and Güzel M (2011) Clinical, pathological and immunohistochemical findings of bovine cutaneous papillomatosis. *Ankara Üniv Vet Fak Derg* 58:161-165.
- Park J, Nickel K, Torres A, Lee D, Lambert P and Kimple R (2014) Human papillomavirus type 16 E7 oncoprotein causes a delay in repair of DNA damage. *Radiother Oncol* 113:337-344.
- Pathania S, Dhama K, Saikumar G, Shahi S and Somvanshi R (2012) Detection and quantification of bovine papilloma virus type 2 (BPV-2) by real-time PCR in urine and urinary bladder lesions in enzootic bovine haematuria (EBH)-affected cows. *Transbound Emerg Dis* 59(1): 79-84.
- Pavelski M, Ollhoff R, Barros-Filho I, Deconto I, Biondo A and Dornbusch P (2014) Evaluation of urine dipstick and cystoscopy in bovine enzootic haematuria. *Semin Ciênc Agr* 35:1369.
- Pennie W and Campo M (1992) Synergism between bovine papillomavirus type 4 and the flavanoid quercetin in cell transformation in vitro. *Virology* 190:19-24.
- Pessoa N (2014) Estudos Sobre a Expressão do Papilomavirus Humano (HPV): Avaliação Comparativa Sobre Lesões Cervicais, Sangue Periférico e Retinoblastomas. Dissertation, Universidade de São Paulo, 140 p. Available in <http://www.teses.usp.br/teses/disponiveis/87/87131/tde-07-052014-090937/pt-br.php>
- Pietras K and Ostman A (2010) Hallmarks of cancer: Interactions with the tumor stroma. *Exp Cell Res* 316:1324-1331.
- Plowright W (1955) Malignant neoplasia of the oesophagus and rumen of cattle in Kenya. *J Comp Pathol* 65:108-114.
- Potocki L, Lewinska A, Klukowska-Rötzler J, Bielak-Zmijewska A, Grabowska W, Rzeszutek I, Kaminska P, Roga E, Bugno-Poniewierska M, Slota E, *et al.* (2014) Sarcoid-derived fibroblasts: Links between genomic instability, energy metabolism and senescence. *Biochimie* 92:163-172.
- Potter D and Baird M (2000) Carcinogenic effects of ptaquiloside in bracken fern and related compounds. *Br J Cancer* 83:914-920.
- Rampias T, Sasaki C and Psyri A (2013) Molecular mechanisms of HPV induced carcinogenesis in head and neck. *Oral Oncol* 50:356-363.
- Rashad AL and Evans CA (1967) Histologic features of virus-rich and virus-poor Shope papillomas of cottontail rabbits. *Cancer Res* 27:1855-1860.
- Rector A and Van Ranst M (2013) Animal papillomaviruses. *Virology* 445:213-223.
- Resendes A, Roperto S, Trapani F, Urraro C, Rodrigues A, Roperto F and Borzacchiello G (2011) Association of bovine papillomavirus type 2 (BPV-2) and urinary bladder tumours in cattle from the Azores archipelago. *Res Vet Sci* 90:526-529.
- Ribeiro-Müller L and Müller M (2014) Prophylactic papillomavirus vaccines. *Clin Dermatol* 32:235-247.
- Ristriani T, Masson M, Nominé Y, Laurent C, Lefevre JF, Weiss E and Travé G (2000) HPV oncoprotein E6 is a structure-dependent DNA-binding protein that recognizes four-way junctions. *J Mol Biol* 296:1189-1203.
- Roberts S (2015) Papillomaviruses. *eLS* 2015:1-11.
- Roperto S, Ambrosio V, Borzacchiello G, Galati P, Paciello O, Russo V and Roperto F (2005) Bovine papillomavirus type-2 (BPV-2) infection and expression of uroplakin IIIb, a novel urothelial cell marker, in urinary bladder tumors of cows. *Vet Pathol* 42:812-818.
- Roperto S, Brun R, Paolini F, Urraro C, Russo V, Borzacchiello G, Pagnini U, Raso C, Rizzo C, Roperto F, *et al.* (2008) Detection of bovine papillomavirus type 2 in the peripheral blood of cattle with urinary bladder tumours: Possible biological role. *J Gen Virol* 89:3027-3033.
- Roperto S, Comazzi S, Ciusani E, Paolini F, Borzacchiello G, Esposito I, Luca R, Russo V, Urraro C, Venuti A, *et al.* (2011) PBMCs are additional sites of productive infection of bovine papillomavirus type 2. *J Gen Virol* 92:1787-1794.
- Roperto S, Borzacchiello G, Esposito I, Riccardi M, Urraro C, Cermola M, Paciello O, Corteggio A and Tate R (2012) Productive infection of bovine papillomavirus type 2 in the placenta of pregnant cows affected with urinary bladder tumors. *PLoS One* 7:e33569.

- Roperto S, Russo V, Leonardi L, Martano M, Corrado F, Riccardi M and Roperto F (2015) Bovine papillomavirus type 13 expression in the urothelial bladder tumours of cattle. *Transbound Emerg Dis* 63(6): 628-634.
- Roperto S, Munday J, Corrado F, Gorla M and Roperto F (2016) Detection of bovine papillomavirus type 14 DNA sequences in urinary bladder tumors in cattle. *Vet Microbiol* 190:1-4.
- Russo V, Roperto F, Esposito I, Ceccarelli D, Zizzo N, Leonardi L, Capparelli R, Borzacchiello G and Roperto S (2016) ERas protein is overexpressed and binds to the activated platelet-derived growth factor β receptor in bovine urothelial tumour cells associated with papillomavirus infection. *Vet J* 212:44-47.
- Sacco A, Siepi F and Crescenzi M (2003) HPV E7 expression in skeletal muscle cells distinguishes initiation of the postmitotic state from its maintenance. *Oncogene* 22:4027-4034.
- Santos E, Silva M, Pontes N, Coutinho L, Paiva S, Castro R and Freitas A (2014) Detection of different bovine papillomavirus types and co-infection in bloodstream of cattle. *Transbound Emerg Dis* 63:e103-e108.
- Schuchat A and Jackson L (2013) Princípios de imunização e uso de vacinas. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J (eds) *Medicina Interna de Harrison*. 18^a ed. Artmed, Porto Alegre, pp 1031-1041.
- Schuck S and Stenlund A (2015) A conserved regulatory module at the C-terminus of the papillomavirus E1 helicase domain controls E1 helicase assembly. *J Virol* 89:1129-1142.
- Schweiger M, You J and Howley P (2006) Bromodomain protein 4 mediates the papillomavirus E2 transcriptional activation function. *J Virol* 80:4276-4285.
- Schweiger M, Ottinger M, You J and Howley P (2007) Brd4-independent transcriptional repression function of the papillomavirus e2 proteins. *J Virol* 81:9612-9622.
- Sedelnikova O and Pilch D (2003) Histone H2AX in DNA damage and repair. *Cancer Biol Ther* 2:233-235.
- Shafiqi-Keramat S, Schellenbacher C, Handisurya A, Christensen N, Reininger B, Brandt S and Kirnbauer R (2009) Bovine papillomavirus type 1 (BPV1) and BPV2 are closely related serotypes. *Virology* 393:1-6.
- Shahin M, Smith B and Prakash A (1999) Bracken carcinogens in the human diet. *Mutat Res - Genet Toxicol Environ Mutagen* 443:69-79.
- Shamanna R, Hoque M, Pe'ery T and Mathews M (2013) Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. *Oncogene* 32:5176-5185.
- Shope R (1937) Immunization of rabbits to infectious papillomatosis. *J Exp Med* 65:219-231.
- Shope R and Hurst E (1933) Infectious papillomatosis of rabbits. *J Exp Med* 58:607-624.
- Sibbet G, Romero-Graillet C, Meneguzzi G and Campo MS (2000) Alpha6 integrin is not the obligatory cell receptor for bovine papillomavirus type 4. *J Gen Virol* 81:327-334.
- Silva F, Cibulski S, Daudt C, Weber M, Guimarães L, Streck A, Mayer F, Riehe P and Canal C (2016) Novel bovine papillomavirus type discovered by rolling-circle amplification coupled with next-generation sequencing. *PLoS One* 11:e0162345.
- Silva MAR, De Albuquerque BMF, Pontes NE, Coutinho LCA, Leitão MCG, Reis MC, Castro RS and Freitas AC (2013a) Detection and expression of bovine papillomavirus in blood of healthy and papillomatosis-affected cattle. *Genet Mol Res* 12:3150-3156.
- Silva M, Batista M, Pontes N, Santos E, Coutinho L, Castro R, Blabino V and Freitas A (2013b) Comparison of two PCR strategies for the detection of bovine papillomavirus. *J Virol Methods* 192:55-58.
- Silvestre O, Borzacchiello G, Nava D, Iovane G, Russo V, Vecchio D, D'Ausilio F, Gault EA, Campo MS and Paciello O (2009) Bovine papillomavirus type 1 DNA and E5 oncoprotein expression in water buffalo fibropapillomas. *Vet Pathol* 46:636-641.
- Stewart A, Rush B and Davis E (2006) The efficacy of intra-tumoral 5-fluorouracil for the treatment of equine sarcoids. *Aust Vet J* 84:101-106.
- Stocco dos Santos RC, Lindsey CJ, Ferraz OP, Pinto JR, Mirandola RS, Benesi FJ, Birgel EH, Pereira CA and Beçak W (1998) Bovine papillomavirus transmission and chromosomal aberrations: An experimental model. *J Gen Virol* 79:2127-2135.
- Syrjänen K (1982) Histological changes identical to those condylomatous lesions found in esophageal squamous cell carcinomas. *Arch Geschwulstforsch* 52:283-294.
- Syrjänen K (2002) HPV infections and oesophageal cancer. *J Clin Pathol* 55:721-728.
- Tan M, White E, Sowa M, Harper J, Aster J and Howley P (2012a) Cutaneous β -human papillomavirus E6 proteins bind Mastermind-like coactivators and repress Notch signaling. *Proc Natl Acad Sci U S A* 109:E1473-E1480.
- Tan M, Yildirim Y, Mahmut S, Dagalp S, Yilmaz V, Kirmizigul A and Gokce E (2012b) A histopathological, immunohistochemical and molecular study of cutaneous bovine papillomatosis. *Kafkas Univ Vet Derg* 18:739-744.
- Taylor S, Toth B, Baseler L, Charney V and Miller M (2014) Lack of correlation between papillomaviral DNA in surgical margins and recurrence of equine sarcoids. *J Equine Vet Sci* 34:722-725.
- Togawa K, Jaskiewicz K, Takahashi H, Meltzer S and Rustgi A (1994) Human papillomavirus DNA in esophageal squamous cell carcinoma. *Gastroenterology* 107:128-136.
- Tokarnia C, Doberreiner J and Peixoto P (2000) Plantas de ação radiomimética. In: Tokarnia C, Doberreiner J and Peixoto P (eds) *Plantas Tóxicas do Brasil*. Helianthus, Rio de Janeiro, pp 178-187.
- Tomita Y, Ogawa T, Jin Z and Shirasawa H (2007) Genus specific features of bovine papillomavirus E6, E7, E5 and E8 proteins. *Virus Res* 124:231-236.
- Tong X, Boll W, Kirchhausen T and Peter M (1998) Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1. *J Virol* 72:476.
- Tsirimonaki E, Neil B, Williams R and Campo M (2003) Extensive papillomatosis of the bovine upper gastrointestinal tract. *J Comp Pathol* 129:93-99.
- Turk N, Zupancic Z, Staresina V, Kovac S, Babic T, Kreszinger M, Curic S, Barbic L and Milas Z (2005) Severe bovine papillomatosis?: Detection of bovine papillomavirus in tumour tissue and efficacy of treatment using autogenous vaccine and parammunity inducer. *Vet Arh* 75:391-397.
- Turner C (2000) Paxillin interactions. *J Cell Sci* 113:4139-4140.
- Van Bresseem M, Cassonnet P, Rector A, Desaintes C, Van Waerebeek K, Alfaro-Shigueto J, Van Ranst M and Orth G (2007) Genital warts in Burmeister's porpoises: Character-

- ization of Phocoena spinipinnis papillomavirus type 1 (PsPV-1) and evidence for a second, distantly related PsPV. *J Gen Virol* 88:1928-1233.
- van Doorslaer K and Burk R (2010) Evolution of humana papillomavirus carcinogenicity. *Adv Virus Res* 77:41-62.
- van Doorslaer K (2013) Evolution of the papillomaviridae. *Virology* 445:11-20.
- Varga J, Oliveira T and Greten F (2014) The architect who never sleeps: Tumor-induced plasticity. *FEBS Lett* 588:2422-2427.
- Venuti A, Paolini F, Nasir L, Corteggio A, Roperto S, Campo M and Borzacchiello G (2011) Papillomavirus E5?: The smallest oncoprotein with many functions. *Mol Cancer* 10:140.
- Vieira C, Lopes J and Velosa J (2013) A case of esophageal squamous cell carcinoma with positive HPV 11. *Gastroenterol Hepatol* 36:311-315.
- Vivanco I and Sawyers C (2002) The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. *Nat Rev Cancer* 2:489-501.
- Wallace N and Galloway D (2014) Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses. *Semin Cancer Biol* 26:30-42.
- Walter-Moura J, Stocco-dos-Santos R, Dagli M, D'Angelino J, Birgel E and Beçak W (1988) Chromosome aberrations in cattle raised on bracken fern pasture. *Experientia* 44:785-88.
- Wang F and Kieff E (2013) *Virologia médica*. In: Longo D, Fauci A, Kasper D, Hauser S, Jameson J and Loscalzo J (eds) *Medicina Interna de Harrison*. 18th ed. Artmed, Porto Alegre, pp 1432-1441.
- Wang J and Roden R (2013) L2, the minor capsid protein of papillomavirus. *Virology* 445:175-186.
- Werness B, Levine A and Howley P (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. *Science* 248:76-79.
- White E and Howley P (2013) Proteomic approaches to the study of papillomavirus - host interactions. *Virology* 435:57-69.
- White E, Kramer R, Hwang J, Pores F, Naetar N, Hahn W, Roberts T, Schaffhausen B, Livingston D and Howley P (2015) Papillomavirus E7 oncoproteins share functions with polyomavirus small T antigens. *J Virol* 89:2857-2865.
- WHO (2013) Global cancer rates could increase by 50% to 15 million by 2020. www.who.int/mediacentre/news/releases/2003/pr27/en.
- William J, Kirubaharan J and Uthumann K (1992) Survey on incidence and complications of bovine cutaneous papillomatosis. *Indian J Vet* 69:842-844.
- Winkler B, Capo V, Reumann W, Ma A, La Porta R, Reilly S, Green P, Richart R and Crum C (1985) Human papillomavirus infection of the esophagus. A clinicopathologic study with demonstration of papillomavirus antigen by the immunoperoxidase technique. *Cancer* 55:149-155.
- Wosiacki S, Barreiro M, Alfieri A and Alfieri A (2005) Semi-nested PCR for detection and typing of bovine Papillomavirus type 2 in urinary bladder and whole blood from cattle with enzootic haematuria. *J Virol Methods* 126:215-219.
- Wosiacki S, Carlos A, Alfieri A and Alfieri A (2002) Bovine papillomavirus type 2 in enzootic haematuria aetiology. *Semin Ciênc Agr* 1:121-130.
- Wosiacki S, Claus M, Alfieri A and Alfieri A (2006) Bovine papillomavirus type 2 detection in the urinary bladder of cattle with chronic enzootic haematuria. *Mem Inst Oswaldo Cruz* 101:635-638.
- Yagui A, Carvalho C, Freitas A, Gustavo L, Góes B, Dagli L, Birgel-Júnior E, Beçak W and Stocco dos Santos R (2006) Papillomatosis in cattle: In situ detection of bovine papillomavirus DNA sequences in reproductive tissues. *Braz J Morphol Sci* 23:525-529.
- Yao Y, Huang W, Yang X, Sun W, Liu X, Cun W and Ma Y (2013) HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: An in silico approach. *Vaccine* 31:2289-2294.
- Yuan Z, Gallagher A, Gault EA, Campo MS and Nasir L (2007) Bovine papillomavirus infection in equine sarcoids and in bovine bladder cancers. *Vet J* 174:599-604.
- Zanier K, Charbonnier S, Baltzinger M, Nominé Y, Altschuh D and Travé G (2005) Kinetic analysis of the interactions of human papillomavirus E6 oncoproteins with the ubiquitin ligase E6AP using surface plasmon resonance. *J Mol Biol* 349:401-412.
- Zanier K, Nominé Y, Charbonnier S, Ruhlmann C, Schultz P, Schweizer J and Travé G (2007) Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species. *Protein Expr Purif* 51:59-70.
- Zaugg N, Nespeca G, Hauser B, Ackermann M and Favrot C (2005) Detection of novel papillomaviruses in canine mucosal, cutaneous and in situ squamous cell carcinomas. *Vet Dermatol* 16:290-298.
- Zhu X, Dong J, Uchida K, Watanabe K, Nakayama H, Goto Y and Haga T (2014) Bovine papillomavirus type 10 with a deletion associated with a lingual papilloma in a cow. *Vet J* 199:303-305.
- Zimmermann H, Degenkolbe R, Bernard H and O'Connor M (1999) The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. *J Virol* 73:6209.
- Zimmermann H, Koh C, Degenkolbe R, O'Connor M, Muller A, Steger G, Chen J, Lui Y, Androphy E and Bernard H (2000) Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. *J Gen Virol* 81:2617-2623.
- zur Hausen H (2009) The search for infectious causes of human cancers: Where and why. *Virology* 392:1-10.
- zur Hausen H (2012) Red meat consumption and cancer?: reasons to suspect involvement of bovine infectious factors in colorectal cancer. *Int J Cancer* 2483:2475-2483.

Associate Editor: Carlos F. M. Menck